References

evrazkar

Евразийский Кардиологический Журнал

Eurasian heart journal

2225-16852305-0748

Евразийская ассоциация кардиологов

10.38109/2225-1685-2024-1-6-85

evrazkar-6443

Research Article

КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ

CLINICAL GUIDELINES

Евразийские рекомендации по диагностике и лечению лёгочной гипертензии (2023)

Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension (2023)

https://orcid.org/0000-0002-9822-4357

Чазова

И. Е.

Chazova

I. E.

Чазова Ирина Евгеньевна, д.м.н., профессор, академик РАН, заместитель генерального директора по научно-экспертной работе, руководитель отдела гипертонии

Москва

Irina E. Chazova, Dr. of Sci. (Med.), Professor, Academician of RAS, Deputy General Director for Scientific and Expert Work, Head of Hypertension Department

Moscow

https://orcid.org/0000-0002-9022-8097

Мартынюк

Т. В.

Martynyuk

T. V.

Мартынюк Тамила Витальевна, д.м.н., руководитель отдела лёгочной гипертензии и заболеваний сердца, Институт клинической кардиологии им. А.Л. Мясникова, ФГБУ «НМИЦ кардиологии им. ак. Е.И. Чазова» Минздрава России; профессор кафедры кардиологии ФДПО, РНИМУ им. Н.И. Пирогова; председатель секции лёгочной гипертензии Российского медицинского общества по артериальной гипертонии

ул. Академика Чазова, д. 15 а, г. Москва 121552телефон/факс: +7-495-414-64-50

Tamila V. Martynyuk, Dr. of Sci. (Med.), Head of the Department of Pulmonary Hypertension and Heart Diseases, A.L. Myasnikov Scientific research institute of clinical cardiology, E.I. Chazov National Medical Research Center of Cardiology; Professor, Department of Cardiology, Faculty of Additional Postgraduate Education, N.I. Pirogov Russian National Medical University; Chairman of the section on pulmonary hypertension, Russian Medical Society for Arterial Hypertension

St. Academician Chazova, 15 a, Moscow 121552Phone/Fax: +7-495-414-6450

trukhiniv@mail.ru

https://orcid.org/0000-0001-8937-1796

Шмальц

А. А.

Shmalts

A. A.

Шмальц Антон Алексеевич, д.м.н., ведущий научный сотрудник, отделение хирургического лечения заболеваний сердца с прогрессирующей лёгочной гипертензией, ФГБУ «НМИЦ сердечно-сосудистой хирургии им. А.Н. Бакулева» Минздрава России; доцент кафедры сердечно-сосудистой хирургии, ФГБОУ ДПО РМАНПО Минздрава России

Москва

Anton A. Shmalts, Dr. of Sci. (Med.), Leading Research Associate, the Department of Surgical Treatment of Cardiac Diseases with Progressive Pulmonary Hypertension, A.N. Bakoulev Scientific Center for Cardiovascular Surgery; Associate Professor, the Department of Cardiovascular Surgery, Russian Medical Academy of Continuing Professional Education

Moscow

https://orcid.org/0000-0003-3292-0912

Грамович

В. В.

Gramovich

V. V.

Грамович Владимир Владимирович, к.м.н., старший научный сотрудник, отдел лёгочной гипертензии и заболеваний сердца

Москва

Vladimir V. Gramovich, Cand. of Sci. (Med.), Senior Researcher, the Department of Pulmonary Hypertension and Heart Diseases

Moscow

https://orcid.org/0000-0001-9853-9087

Данилов

Н. М.

Danilov

N. M.

Данилов Николай Михайлович, д.м.н., ведущий научный сотрудник, отдел гипертонии

Москва

Nikolay M. Danilov, Dr. of Sci. (Med.), Leading Researcher of Hypertension Department

Moscow

https://orcid.org/0000-0001-8319-3714

Веселова

Т. Н.

Veselova

T. N.

Веселова Татьяна Николаевна, д.м.н., старший научный сотрудник, отдел томографии

Москва

Tatiana N. Veselova, Dr. of Sci. (Med.), Leading Researcher of The Tomography Department

Moscow

https://orcid.org/0000-0003-0972-7030

Коробкова

И. З.

Korobkova

I. Z.

Коробкова Ирина Захаровна, к.м.н., заведующая отделением рентгенологии, Институт клинической кардиологии им. А.Л. Мясникова, ФГБУ «НМИЦ кардиологии им. ак. Е.И. Чазова» Минздрава России; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России

Москва

Irina Z. Korobkova, Cand. of Sci. (Med.), Нead of the Department of Radiology, A.L. Myasnikov Scientific research institute of clinical cardiology, E.I. Chazov National Medical Research Center of Cardiology; Russian Medical Academy of Continuing Professional Education

Moscow

https://orcid.org/0000-0003-2172-9776

Сарыбаев

А. Ш.

Sarybaev

A. Sh.

Сарыбаев Акпай Шогаибович, д.м.н., профессор, ведущий научный сотрудник

Бишкек

Akpaj Sh. Sarybaev, Dr. of Sci. (Med.), Professor, Leading Researcher

Bishkek

https://orcid.org/0000-0001-8377-2388

Стукалова

О. В.

Stukalova

O. V.

Стукалова Ольга Владимировна, к.м.н., старший научный сотрудник, отдел томографии

Москва

Ol’ga V. Stukalova, Cand. of Sci. (Med.), Senior Researcher, the tomography department

Moscow

https://orcid.org/0000-0001-5655-3913

Азизов

В. А.

Azizov

V. A.

Азизов Васадат Али-Оглы, д.м.н., профессор, заведующий кафедрой внутренних болезней

Баку

Vasadat A. Azizov, Dr. of Sci. (Med.), Professor, Head of the Department of Internal Diseases

Baku

https://orcid.org/0000-0002-4642-3610

Барбараш

О. Л.

Barbarash

O. L.

Барбараш Ольга Леонидовна, д.м.н., профессор, академик РАН, директор, ФГБНУ «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний» Министерства науки и высшего образования России; заведующая кафедрой кардиологии и сердечно-сосудистой хирургии, ФГБОУ ВО КемГМУ

Кемерово

Olga L. Barbarash, Dr. of Sci. (Med.), Professor, Academician of RAS, director, Research Institute for Complex Problems of Cardiovascular Diseases; Head of the Department of Cardiology and Cardiovascular Surgery, Kemerovo State Medical University

Kemerovo

https://orcid.org/0000-0002-4510-6197

Галявич

А. С.

Galyavich

A. S.

Галявич Альберт Сарварович, д.м.н., профессор, академик АН РТ, руководитель направления кардиологии, ГАУЗ «Межрегиональный клинико-диагностический центр», главный кардиолог Приволжского Федерального Округа

Казань

Albert S. Galyavich, Dr. of Sci. (Med.), Academician of the Academy of Sciences of the Republic of Tatarstan, Head of Cardiology Department, Interregional Clinical Diagnostic Center, Chief Cardiologist of the Volga Federal District

Kazan

https://orcid.org/0000-0002-4193-3320

Горбачевский

С. В.

Gorbachevsky

S. V.

Горбачевский Сергей Валерьевич, д.м.н., профессор, главный научный сотрудник, отделение хирургического лечения заболеваний сердца с прогрессирующей лёгочной гипертензией, ФГБУ «НМИЦ сердечно-сосудистой хирургии им. А.Н. Бакулева» Минздрава России; профессор кафедры сердечно-сосудистой хирургии, ФГБОУ ДПО РМАНПО Минздрава России

Москва

Sergey V. Gorbachevsky, Dr. of Sci.(Med.), Professor, Chief Researcher, the Department of Surgical Treatment of Cardiac Diseases with Progressive Pulmonary Hypertension, A.N. Bakoulev Scientific Center for Cardiovascular Surgery; Professor, the Department of Cardiovascular Surgery, Russian Medical Academy of Continuing Professional Education

Moscow

https://orcid.org/0000-0001-7572-8264

Медведева

Е. А.

Medvedeva

E. A.

Медведева Елена Александровна, д.м.н., врач-кардиолог, заведующая отделом консультативной работы и профилактической кардиологии

Минск

Elena A. Medvedeva, Dr. of Sci. (Med.), cardiologist, Head of Department of Advisory work and Рreventive cardiology

Minsk

https://orcid.org/0000-0002-0200-852X

Матчин

Ю. Г.

Matchin

Yu. G.

Матчин Юрий Георгиевич, д.м.н., профессор, руководитель отдела, отдел рентгенэндоваскулярных методов диагностики и лечения в амбулаторных условиях

Москва

Yuriy G. Matchin, Dr. of Sci. (Med.), Professor, Head of the Department of X-ray endovascular diagnostic methods and treatment on an outpatient basis

Moscow

https://orcid.org/0000-0003-2854-1952

Мукаров

М. А.

Mukarov

M. A.

Мукаров Мурат Аманжолович, к.м.н., директор, клинико-академический департамент кардиологии

Нур-Султан

Murat A. Mukarov, Cand. of Sci. (Med.), director, Clinical and Academic Department

Nur-Sultan

https://orcid.org/0000-0003-1564-7619

Наконечников

С. Н.

Nakonechnikov

S. N.

Наконечников Сергей Николаевич, д.м.н., профессор, кафедра кардиологии

Москва

Sergey N. Nakonechnikov, Dr. of Sci. (Med.), Professor, Faculty of Additional Postgraduate Education

Moscow

https://orcid.org/0000-0002-7688-7176

Филиппов

Е. В.

Filippov

E. V.

Филиппов Евгений Владимирович, д.м.н., профессор, заведующий кафедрой, кафедра поликлинической терапии и профилактической медицины, Рязанский государственный медицинский университет им. ак. И.П. Павлова; главный специалист-кардиолог департамента здравоохранения Рязанской области

Рязань

Evgeniy V. Filippov, Dr. of Sci. (Med.), Professor, Head of department, Department of Polyclinic Therapy and Preventive Medicine; Chief cardiologist of the Department of Health of the Ryazan region

Ryazan

https://orcid.org/0000-0002-6619-3875

Черногривов

И. Е.

Chernogrivov

I. E.

Черногривов Игорь Евгеньевич, д.м.н., заведующий, отделение хирургического лечения заболеваний сердца с прогрессирующей лёгочной гипертензией

Москва

Igor E. Chernogrivov, Dr. of Sci. (Med.), Head of the Department, the Department of Surgical Treatment of Cardiac Diseases with Progressive Pulmonary Hypertension

Moscow

Институт клинической кардиологии им. А.Л. Мясникова, ФГБУ «НМИЦ кардиологии им. ак. Е.И. Чазова» Минздрава РоссииРоссияA.L. Myasnikov Scientific research institute of clinical cardiology, E.I. Chazov National Medical Research Center of CardiologyRussian Federation

Институт клинической кардиологии им. А.Л. Мясникова, ФГБУ «НМИЦ кардиологии им. ак. Е.И. Чазова» Минздрава России; РНИМУ им. Н.И. Пирогова; Российское медицинское общество по артериальной гипертонииРоссияA.L. Myasnikov Scientific research institute of clinical cardiology, E.I. Chazov National Medical Research Center of Cardiology; N.I. Pirogov Russian National Medical University; Russian Medical Society for Arterial HypertensionRussian Federation

ФГБУ «НМИЦ сердечно-сосудистой хирургии им. А.Н. Бакулева» Минздрава России; ФГБОУ ДПО РМАНПО Минздрава РоссииРоссияA.N. Bakoulev Scientific Center for Cardiovascular Surgery; Russian Medical Academy of Continuing Professional EducationRussian Federation

Институт клинической кардиологии им. А.Л. Мясникова, ФГБУ «НМИЦ кардиологии им. ак. Е.И. Чазова» Минздрава России; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияA.L. Myasnikov Scientific research institute of clinical cardiology, E.I. Chazov National Medical Research Center of Cardiology; Russian Medical Academy of Continuing Professional EducationRussian Federation

Национальный центр кардиологии и терапии им. академика М.М. Миррахимова при Минздраве Киргизской РеспубликиКыргызстанMM. Mirrakhimov National Center of Cardiology and Internal TherapyKyrgyzstan

1-й Азербайджанский Медицинский УниверситетАзербайджан1st Azerbaijan Medical UniversityAzerbaijan

ФГБНУ «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний» Министерства науки и высшего образования России; ФГБОУ ВО КемГМУРоссияResearch Institute for Complex Problems of Cardiovascular Diseases; Kemerovo State Medical UniversityRussian Federation

ГАУЗ «Межрегиональный клинико-диагностический центр»РоссияInterregional Clinical Diagnostic CenterRussian Federation

Республиканский научно-практический центр «Кардиология»БеларусьRepublican Scientific and Practical Center «Cardiology»Belarus

Национальный научный кардиохирургический центрКазахстанNational Research Cardiac Surgery CenterKazakhstan

ФДПО РНИМУ им. Н.И. ПироговаРоссияN.I. Pirogov Russian National Medical UniversityRussian Federation

Рязанский государственный медицинский университет им. ак. И.П. ПавловаРоссияRyazan State Medical UniversityRussian Federation

ФГБУ «НМИЦ сердечно-сосудистой хирургии им. А.Н. Бакулева» Минздрава РоссииРоссияA.N. Bakoulev Scientific Center for Cardiovascular SurgeryRussian Federation

2024

11032024

01685

Copyright © Чазова И.Е., Мартынюк Т.В., Шмальц А.А., Грамович В.В., Данилов Н.М., Веселова Т.Н., Коробкова И.З., Сарыбаев А.Ш., Стукалова О.В., Азизов В.А., Барбараш О.Л., Галявич А.С., Горбачевский С.В., Медведева Е.А., Матчин Ю.Г., Мукаров М.А., Наконечников С.Н., Филиппов Е.В., Черногривов И.Е., 2024

2024

Чазова И.Е., Мартынюк Т.В., Шмальц А.А., Грамович В.В., Данилов Н.М., Веселова Т.Н., Коробкова И.З., Сарыбаев А.Ш., Стукалова О.В., Азизов В.А., Барбараш О.Л., Галявич А.С., Горбачевский С.В., Медведева Е.А., Матчин Ю.Г., Мукаров М.А., Наконечников С.Н., Филиппов Е.В., Черногривов И.Е.

Chazova I.E., Martynyuk T.V., Shmalts A.A., Gramovich V.V., Danilov N.M., Veselova T.N., Korobkova I.Z., Sarybaev A.S., Stukalova O.V., Azizov V.A., Barbarash O.L., Galyavich A.S., Gorbachevsky S.V., Medvedeva E.A., Matchin Y.G., Mukarov M.A., Nakonechnikov S.N., Filippov E.V., Chernogrivov I.E.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.heartj.asia/jour/article/view/6443

лёгочная гипертензиялёгочная артериальная гипертензияхроническая тромбоэмболическая лёгочная гипертензиядиагностикахирургическое лечениеэндоваскулярное лечениеспецифическая терапияклинические рекомендации

pulmonary hypertensionpulmonary arterial hypertensionchronic thromboembolic pulmonary hypertensiondiagnosissurgical treatmentendovascular treatmentspecific therapyguidelines

References1

Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53:1801913. https://doi.org/10.1183/13993003.01913-2018

Humbert M, Kovacs G, Hoeper MM, et al. ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). Eur Heart J 2022; 43(38):3618–3731. http://dx.doi.org/10.1093/eurheartj/ehac237

Чазова И.Е., Авдеев С.Н., Царева Н.А., др. Клинические рекомендации по диагностике и лечению лёгочной гипертензии. Терапевтический архив 2014;9:4–23.

Chazova IE, Avdeev SN, Tsareva NA, Volkov AV, Martynyuk TV, Nakonechnikov SN. Clinical guidelines for the diagnosis and treatment of pulmonary hypertension. Terapevticheskii Arkhiv. 2014;86(9):4-23 (In Russ.)

Мартынюк Т.В. Лёгочная гипертензия: диагностика и лечение. Москва, 2018. Серия Библиотека ФГБУ «НМИЦ кардиологии» Минздрава России. ISBN 978-5-6040008-0-9

Martynyuk T.V. Pulmonary hypertension: diagnosis and treatment. Moscow, 2018. Series Library “National Medical Research Center of Cardiology” of the Ministry of Health of Russia (In Russ.). ISBN 978-5-6040008-0-9

Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Respir J 2015;46(4):903-975. http://dx.doi.org/10.1183/13993003.01177-2015

Чазова И.Е., Мартынюк Т.В., Филиппов Е.В., др. Клинические рекомендации по диагностике и лечению хронической тромбоэмболической лёгочной гипертензии. (I часть). Терапевтический архив 2016; 88(9):90-101. https://doi.org/10.17116/terarkh201688990-101

Chazova I.E., Martynyuk T.V., Filippov E.V., others. Clinical guidelines for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension. (Part I). Therapeutic Archive 2016;88(9):90-101 (in Russ.). https://doi.org/10.17116/terarkh201688990-101

Kim N.H., Delcroix M., Jais X. et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2019; 53:1801915. https://doi.org/10.1183/13993003.01915-2018

Wilkens H, Konstantinides S, Lang IM, Bunck AC, Gerges M, Gerhardt F, Grgic A, Grohé C, Guth S, Held M, Hinrichs JB, Hoeper MM, Klepetko W, Kramm T, Krüger U, Lankeit M, Meyer BC, Olsson KM, Schäfers HJ, Schmidt M, Seyfarth HJ, Ulrich S, Wiedenroth CB, Mayer E. Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018 Dec 1;272S:69-78. https://doi.org/10.1016/j.ijcard.2018.08.079

Чазова И.Е., Мартынюк Т.В., Валиева З.С., др. Евразийские клинические рекомендации по диагностике и лечению лёгочной гипертензии (2019). Евразийский Кардиологический Журнал 2020; 1:78-122. https://doi.org/10.38109/2225-1685-2020-1-78-122

Chazova I.E., Martynyuk T.V., Valieva Z.S., Azizov V.A., Barbarash O.L., Veselova T.N., Galyavich A.S., Gorbachevsky S.V., Zelveian P.A., Lazareva I.V., Mukarov M.A., Nakonetchnikov S.N., Saidova M.A., Sarybaev A.Sh., Stukalova O.V., Shalaev S.V., Shmalts A.A. Eurasian clinical guidelines on diagnosis and treatment of pulmonary hypertension (2019). Eurasian heart journal. 2020;(1):78-122. (In Russ.) https://doi.org/10.38109/2225-1685-2020-1-78-122

Чазова И.Е., Мартынюк Т.В. Лёгочная гипертензия. – Москва. Практика. 2015; 928с.

Chazova I.E., Martynyuk T.V. Pulmonary hypertension. – Moscow. Practice. 2015; 928 pp. (In Russ.)

Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111:3105–3111. https://doi.org/10.1161/circulationaha.104.488486

Чазова И.Е., Архипова О.А., Мартынюк Т.В. Лёгочная артериальная гипертензия в России: анализ шестилетнего наблюдения по данным Национального регистра. Терапевтический архив 2019; 91(1):10–31. https://doi.org/10.26442/00403660.2019.01.000024

Chazova IE, Arkhipova OA, Martynyuk TV. Pulmonary arterial hypertension in Russia: six-year observation analysis of the National Registry. Ter Arkh. 2019 Mar 10;91(1):24-31. (in Russ.). https://doi.org/10.26442/00403660.2019.01.000024

Chazova IE, Martynyuk TV, Valieva ZS, et al. Clinical and Instrumental Characteristics of Newly Diagnosed Patients with Various Forms of Pulmonary Hypertension according to the Russian National Registry. BioMed Research International. 2020:6836973. PMID: 32626754. https://doi.org/10.1155/2020/6836973

Чазова И.Е., Горбачевский С.В., Мартынюк Т.В., др. Евразийские рекомендации по диагностике и лечению лёгочной гипертензии, ассоциированной с врождёнными пороками сердца у взрослых (2021). Евразийский кардиологический журнал. 2022;2:6-70. https://doi.org/10.38109/2225-1685-2022-2-6-7

Chazova I.E., Gorbachevskij S.V., Martynyuk T.V., Shmal’c A.A., Valieva Z.S., Baryshnikova I.Yu., Glushko L.A., Gramovich V.V., Azizov V.A., Veselova T.N., Danilov N.M., Zelveyan P.A., Ivanov S.N., Lazareva I.V., Matchin Yu.G., Mukarov M.A., Nakonechnikov S.N., Sarybaev A.Sh., Stukalova O.V., Shalaev S.V. Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension associated with congenital heart defects in adults (2021). Eurasian heart journal. 2022;(2):6-70. (In Russ.). https://doi.org/10.38109/2225-1685-2022-2-6-70

Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008;177:108–113. https://doi.org/10.1164/rccm.200704-541oc

Montani D, Price LC, Dorfmuller P, et al. Pulmonary veno-occlusive disease. Eur Respir J 2009;33:189–200. https://doi.org/10.1183/09031936.00090608

Rosenkranz S, Gibbs JS, Wachter R, De Marco T, Vonk-Noordegraaf A, Vachiéry JL. Left ventricular heart failure and pulmonary hypertension. Eur Heart J. 2016 Mar 21;37(12):942-54. https://doi.org/10.1093/eurheartj/ehv512

Мартынюк Т.В. «Лёгочная гипертензия вследствие патологии левых отделов сердца». Глава в руководстве для врачей «Лёгочная гипертензия» под ред. Авдеева С.Н. (2 издание). ГЭОТАР-МЕДИА, Москва, 2019. С. 213-254.

Martynyuk T.V. «Pulmonary hypertension due to pathology of the left heart». Chapter in the manual for doctors «Pulmonary hypertension», ed. Avdeeva S.N. (2nd edition). GEOTAR-MEDIA, Moscow, 2019. pp. 213-254 (in Russ.)

Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:189-194. https://doi.org/10.1164/rccm.200401-006oc

Maripov A, Mamazhakypov A, Karagulova G, et al. High altitude pulmonary hypertension with severe right ventricular dysfunction. Int J Cardiol 2013; 168(3):e89–e90. https://doi.org/10.1016/j.ijcard.2013.07.129

Leon-Velarde F, Maggiorini M, Reeves JT, et al. Consensus statement on chronic and subacute high altitude diseases. High Alt Med Biol 2005; 6:147-157. https://doi.org/10.1089/ham.2005.6.147

Авдеев С.Н., Барбараш О.Л., Баутин А.Е., Волков А.В., Веселова Т.Н., Галявич А.С., Гончарова Н.С., Горбачевский С.В., Данилов Н.М., Еременко А.А., Мартынюк Т.В., Моисеева О.М., Саидова М.А., Сергиенко В.Б., Симакова М.А., Стукалова О.В., Чазова И.Е., Чернявский А.М., Шалаев С.В., Шмальц А.А., Царева Н.А. Легочная гипертензия, в том числе хроническая тромбоэмболическая легочная гипертензия. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(12):4683. https://doi.org/10.15829/1560-4071-2021-4683

Avdeev S.N., Barbarash O.L., Bautin A.E., Volkov A.V., Veselova T.N., Galyavich A.S., Goncharova N.S., Gorbachevsky S.V., Danilov N.M., Eremenko A.A., Martynyuk T.V., Moiseeva O.M., Saidova M.A., Sergienko V.B., Simakova M.A., Stukalova O.V., Chazova I.E., Chernyavsky A.M., Shalaev S.V., Shmalts A.A., Tsareva N.A. 2020 Clinical practice guidelines for Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. Russian Journal of Cardiology. 2021;26(12):4683. (In Russ.) https://doi.org/10.15829/1560-4071-2021-4683

Montani D, Girerd B, Jais X, et al. Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation. Eur Respir J 2020; 58: 2004229. https://doi.org/10.1183/13993003.04229-2020

Kovacs G, Berghold A, Scheidl S, et al. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009; 34(4):888–894. https://doi.org/10.1183/09031936.00145608

Pieske B, Tschope C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 2019; 40: 3297–3317. https://doi.org/10.1093/eurheartj/ehz641

Maron BA, Brittain EL, Hess E, et al. Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study. Lancet Respir Med 2020; 8:873–884. https://doi.org/10.1016/s2213-2600(20)30317-9

Frost A, Badesch D, Simon JR, et al. Diagnosis of pulmonary hypertension. Eur Respir J 2019; 53:1801904. https://doi.org/10.1183/13993003.01904-2018

Morrell N, Adnot S, Archer S, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54:S20-S31. https://doi.org/10.1016/j.jacc.2009.04.018

Olschewski A, Berghausen EM, Eichstaedt CA, et al. Pathobiology, pathology and genetics of pulmonary hypertension: Update from the Cologne Consensus Conference 2018. Int J Cardiol 2018; 272S:4–10. https://doi.org/10.1016/j.ijcard.2018.09.070

Rosenkranz S, Lang IM, Blindt R, et al. Pulmonary hypertension associated with left heart disease: Updated Recommendations of the Cologne Consensus Conference 2018. Int J Cardiol 2018; 272S:53–62. https://doi.org/10.1016/j.ijcard.2018.08.080

Hurdman J, Condliffe R, Elliot CA, et al. Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J 2013; 41:1292–1301. https://doi.org/10.1183/09031936.00079512

Nathan SD, Barbera JA, Gaine SP, et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J 2019; 53:1801914. https://doi.org/10.1183/13993003.01914-2018

Наконечников С.Н., Зыков К.А., Мартынюк Т.В., др. Профиль провоспалительных маркеров у пациентов с различными формами лёгочной гипертензии. Системные гипертензии 2010; 3:61-67. https://doi.org/10.26442/SG28888

Nakonechnikov SN, Zykov KA, Martynyuk TV, Masenko VP, Rvacheva AV, Ratova LG, Matvienko OO, Andreeva YA, Chazova IE. Profil' provospalitel'nykh markerov u patsientov s razlichnymi formami legochnoy gipertenzii. Systemic Hypertension 2010;7(3):61-66. (in Russ.) https://doi.org/10.26442/SG28888

Simonneau G, Torbicki A, Dorfmüller P, Kim N. The pathophysiology of chronic thromboembolic pulmonary hypertension. Eur Respir Rev 2017; 26(143):160112. https://doi.org/10.1183/16000617.0112-2016

Бокерия Л.А., Горбачевский С.В., Шмальц А.А. Лёгочная артериальная гипертензия, ассоциированная с врождёнными пороками сердца у взрослых. Методическое пособие./ НЦССХ им. А. Н. Бакулева РАМН, 2016 г. ISBN: 978-5-7982-0368-0

Bockeria L.A., Gorbachevsky S.V., Shmalts A.A. Pulmonary arterial hypertension associated with congenital heart defects in adults. Methodological manual./ Bakulev Center for Cardiovascular Surgery, 2016. (in Russ.). ISBN: 978-5-7982-0368-0

Hoeper MM, Humbert M, Souza R, et al. A global view of pulmonary hypertension. Lancet Respir Med 2016; 4:306–322. https://doi.org/10.1016/s2213-2600(15)00543-3

Leber L, Beaudet A, Muller A. Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review. Pulm Circ 2021; 11:2045894020977300. https://doi.org/10.1177/2045894020977300

Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107(2):216–223. https://doi.org/10.7326/0003-4819-107-2-216

Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122 (2):156–163. https://doi.org/10.1161/circulationaha.109.911818

Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010; 137(2):376–387. https://doi.org/10.1378/chest.09-1140

Hoeper MM, Huscher D, Ghofrani HA, et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol 2013; 168(2):871–880. https://doi.org/10.1016/j.ijcard.2012.10.026

Чазова И.Е., Архипова О.А., Валиева З.С., др. Лёгочная гипертензия в России: первые результаты национального регистра. Терапевтический архив 2014; 86(9):56-64.

Chazova IE, Arkhipova OA, Valieva ZS, Nakonechnikov SN, Martynyuk TV. Pulmonary hypertension in Russia: The first results of the national register. Terapevticheskii Arkhiv. 2014;86(9):56-64. (In Russ.)

Naeije R. Pulmonary hypertension at high altitude. Eur Respir J 2019; 53(6):1900985. https://doi.org/10.1183/13993003.00985-2019

Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001; 345:1465-1472. https://doi.org/10.1056/nejmra010902

Delcroix M, Torbicki A, Gopalan D, et al. ERS statement on chronic thromboembolic pulmonary hypertension. Eur Respir J 2021; 57(6):2002828. https://doi.org/10.1183/13993003.02828-2020

Kramm T, Wilkens H, Fuge J, Schäfers HJ, Guth S, Wiedenroth CB, Weingard B, Huscher D, Pittrow D, Cebotari S, Hoeper MM, Mayer E, Olsson KM. Incidence and characteristics of chronic thromboembolic pulmonary hypertension in Germany. Clin Res Cardiol. 2018 Jul;107(7):548-553. https://doi.org/10.1007/s00392-018-1215-5

Чазова И.Е., Валиева З.С., Наконечников С.Н. др. Особенности клинико-функционального и гемодинамического профиля, лекарственной терапии и оценка прогноза у пациентов с неоперабельной хронической тромбоэмболической и идиопатической лёгочной гипертензией по данным Российского регистра. Терапевтический архив 2019; 91(9):77-87. https://doi.org/10.26442/00403660.2019.09.000343

Chazova IE, Valieva ZS, Nakonechnikov SN, Taran IN, Martynyuk TV. Features of clinical, functional and hemodynamics profile, medical treatment and prognosis evaluation in patients with inoperable chronic thromboembolic pulmonary hypertension and idiopathic pulmonary arterial hypertension according to the Russian registry. Terapevticheskii arkhiv 2019;91(9):77-87. (in Russ.) https://doi.org/10.26442/00403660.2019.09.000343

Boucly A, Cottin V, Nunes H, et al. Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. Eur Respir J 2017; 50:1700465. https://doi.org/10.1183/13993003.00465-2017

Чазова И.Е., Мартынюк Т.В., Валиева З.С., Азизов В.А., Акчурин Р.С., Аншелес А.А., Васильцева О.Я., Веселова Т.Н., Галявич А.С., Горбачевский С.В., Данилов Н.М., Едемский А.Г., Зелвеян П.А., Лазарева И.В., Матчин Ю.Г., Мершин К.В., Мукаров М.А., Наконечников С.Н., Саидова М.А., Сарыбаев А.Ш., Сергиенко В.Б., Стукалова О.В., Филиппов Е.В., Чернявский А.М., Чернявский М.А., Шалаев С.В., Шмальц А.А. Евразийские рекомендации по диагностике и лечению хронической тромбоэмболической легочной гипертензии (2020). Евразийский Кардиологический Журнал. 2021;(1):6-43. https://doi.org/10.38109/2225-1685-2021-1-6-43

Chazova I.E., Martynyuk T.V., Valieva Z.S., Azizov V.A., Akchurin R.S., Ansheles A.A., Vasiltseva O.Ya., Veselova T.N., Galyavich A.S., Gorbachevsky S.V., Danilov N.M., Edemskiy A.G., Zelveyan P.A., Lazareva I.V., Matchin Yu.G., Mershin K.V., Mukarov M.A., Nakonechnikov S.N., Saidova M.A., Sarybaev A.Sh., Sergienko V.B., Stukalova O.V., Filippov E.V., Chernyavsky A.M., Chernyavsky M.A., Shalaev S.V., Shmalts A.A. Eurasian association of cardiology (eac) guidelines for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension (2020). Eurasian heart journal. 2021;(1):6-43. (In Russ.) https://doi.org/10.38109/2225-1685-2021-1-6-43

Алокова Ф.Х., Блинова Е.В., Сахнова Т.А., Архипова О.А., Рябыкина Г.В., Саидова М.А., Мартынюк Т.В., Чазова И.Е. Изменения электрокардиограммы в 12 отведениях у больных с идиопатической легочной гипертензией. Медицинский алфавит. 2018;4(36):29-35.

Alokova F.Kh., Blinova E.V., Sakhnova T.A., Arkhipova O.A., Ryabykina G.V., Saidova M.A., Martynyuk T.V., Chazova I.Ye. Changes of the electrocardiogram in 12 leads in patients with idiopathic pulmonary hypertension. Medical alphabet. 2018;4(36):29-35. (In Russ.)

Klok FA, Surie S, Kempf T, et al. A simple non-invasive diagnostic algorithm for ruling out chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. Thromb Res 2011;128:21-26. https://doi.org/10.1016/j.thromres.2011.03.004

Tongers J, Schwerdtfeger B, Klein G, et al. Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J 2007; 153:127-132. https://doi.org/10.1016/j.ahj.2006.09.008

Kamphuis VP, Haeck ML, Wagner GS, et al. Electrocardiographic detection of right ventricular pressure overload in patients with suspected pulmonary hypertension. J Electrocardiol 2014; 47(2):175-182. https://doi.org/10.1016/j.jelectrocard.2013.10.010

Сахнова Т.А., Блинова Е.В., Белевская А.А., др. Сопоставление интегральных показателей векторкардиограммы с данными эхокардиографического исследования у больных идиопатической и хронической тромбоэмболической лёгочной гипертензией. Терапевтический архив 2019;3:11-16. https://doi.org/10.26442/00403660.2019.03.000043

Sakhnova TA, Blinova EV, Belevskaya AA, Saidova MA, Arkhipova OA, Yurasova ES, Alokova FH, Martynyuk TV, Chazova IY. Comparison of the integral indices of the vectorcardiogram with the data of echocardiography in patients with idiopathic and chronic thromboembolic pulmonary hypertension. Terapevticheskii arkhiv 2019;91(3):11-16. (in Russ.) https://doi.org/10.26442/00403660.2019.03.000043

Remy-Jardin M, Ryerson CJ, Schiebler ML, et al. Imaging of pulmonary hypertension in adults: a position paper from the Fleischner Society. Eur Respir J 2021;57:2004455. https://doi.org/10.1183/13993003.04455-2020

Коробкова И.З., Лазуткина В.К., Низовцова Л.А., Ридэн Т.В. Методические аспекты рентгенологической оценки лёгочной гипертензии. ВРР 2015;4:45-53. https://doi.org/10.20862/0042-4676-2015-0-4-14-21

Korobkova I.K., Lazutkina V.K., Nizovtsova L.A., Riden T.V. Radiographic assessment of pulmonary hypertension: Methodical aspects. Journal of radiology and nuclear medicine. 2015;(4):46-53. (In Russ.) https://doi.org/10.20862/0042-4676-2015-0-4-14-21

Ascha M, Renapurkar RD, Tonelli AR. A review of imaging modalities in pulmonaryhypertension. Ann Thorac Med 2017;12:61-73. https://doi.org/10.4103/1817-1737.203742

Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Pulmonary function in primary pulmonary hypertension. J Am Coll Cardiol 2003; 41:1028-1035. https://doi.org/10.1016/s0735-1097(02)02964-9

Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults:a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010; 23:685–713. https://doi.org/10.1016/j.echo.2010.05.010

Белевская А.А., Дадачева З.Х., Саидова М.А., др. Возможности эхокардиографии в диагностике лёгочной гипертензии и оценке ремоделирования сердца. Лечебное дело 2015;1:111-121.

Belevskaya A.A., Dadacheva Z.Kh., Saidova M.A., Martynyuk T.V., Chazova I.E. The Role of Echocardiography in Diagnosis of Pulmonary Hypertension and Assessment of Heart Remodeling. General Medicine 2015;1:111-121. (in Russ.)

Rich JD, Shah SJ, Swamy RS et al. Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. Chest 2011; 139(5):988-993. https://doi.org/10.1378/chest.10-1269

Finkelhor RS, Lewis SA, Pillai D. Limitations and strengths of doppler/echo pulmonary artery systolic pressure-right heart catheterization correlations: a systematic literature review. Echocardiography 2015;32(1):10-18. https://doi.org/10.1111/echo.12594

Magnino C, Omede P, Avenatti E, et al. Inaccuracy of right atrial pressure estimates through inferior vena cava indices. Am J Cardiol 2017; 120 (9):1667-1673. https://doi.org/10.1016/j.amjcard.2017.07.069

Berger M, Haimowitz A, Van Tosh A, et al. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol 1985; 6 (2):359-65. https://doi.org/10.1016/s0735-1097(85)80172-8

Greiner S, Jud A, Aurich M et al. Reliability of noninvasive assessment of systolic pulmonary artery pressure by Doppler echocardiography compared to right heart catheterization: analysis in a large patient population. J Am Heart Assoc. 2014; 3(4): e001103. https://doi.org/10.1161/jaha.114.001103

Ni JR, Yan PJ, Liu SD, et al. Diagnostic accuracy of transthoracic echocardiography for pulmonary hypertension: a systematic review and meta-analysis. BMJ Open 2019; 22;9(12):e033084. https://doi.org/10.1136/bmjopen-2019-033084

Amsallem M, Sternbach JM, Adigopula S, et al. Addressing the Controversy of Estimating Pulmonary Arterial Pressure by Echocardiography. J Am Soc Echocardiogr 2016; 29 (2):93-102 https://doi.org/10.1016/j.echo.2015.11.001

Willis J, Henry F, Wild C, et al. Echocardiographic probability of pulmonary hypertension: a real world audit comparing 2015 and 2022 ESC guidelines. Abstract presented at ESC Congress 2023. Eur Heart J 2023; Vol. 44, Issue Supplement_October 2023; in press.

D'Alto M, Romeo E, Argiento P, et al. Accuracy and precision of echocardiography versus right heart catheterization for the assessment of pulmonary hypertension. Int J Cardiol 2013;168(4):4058-62. https://doi.org/10.1016/j.ijcard.2013.07.005

Dimopoulos K, Condliffe R, Tulloh RMR, et al. Echocardiographic Screening for Pulmonary Hypertension in Congenital Heart Disease: JACC Review Topic of the Week. J Am Coll Cardiol 2018; 72(22):2778-2788. https://doi.org/10.1016/j.jacc.2018.08.2201

Nagueh SF, Middleton KJ, Kopelen HA, et al. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997; 30(6):1527-33. https://doi.org/10.1016/s0735-1097(97)00344-6

Todaro MC, Carerj S, Zito C, et al. Echocardiographic evaluation of right ventricular-arterial coupling in pulmonary hypertension. Am J Cardiovasc Dis. 2020;10(4):272-283. PMID: 33224574

Vizza CD, Lang IM, Badagliacca R, et al. Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension? Am J Respir Crit Care Med 2022; 205(7):751-760. https://doi.org/10.1164/rccm.202109-2079pp

Wright LM, Dwyer N, Celermajer D, et al. Follow-Up of Pulmonary Hypertension With Echocardiography. JACC Cardiovasc Imaging 2016; 9 (6):733-46. https://doi.org/10.1016/j.jcmg.2016.02.022

Wright L, Dwyer N, Wahi S, Marwick TH. Relative Importance of Baseline and Longitudinal Evaluation in the Follow-Up of Vasodilator Therapy in Pulmonary Arterial Hypertension. JACC Cardiovasc Imaging. 2019 Nov;12(11 Pt 1):2103-2111. https://doi.org/10.1016/j.jcmg.2018.08.017

Farmakis IT, Demerouti E, Karyofyllis P, et al. Echocardiography in Pulmonary Arterial Hypertension: Is It Time to Reconsider Its Prognostic Utility? J Clin Med. 2021;10(13):2826. https://doi.org/10.3390/jcm10132826

Restrepo CS, Carswell AP. Aneurysms and pseudoaneurysms of the pulmonary vasculature. Semin Ultrasound CT MR. 2012;33(6):552-66. https://doi.org/10.1053/j.sult.2012.04.001

Berger T, Siepe M, Simon B, Beyersdorf F, Chen Z, Kondov S, Schlett CL, Bamberg F, Tarkhnishvili A, Chikvatia S, Czerny M, Rylski B, Kreibich M. Pulmonary artery diameter: means and normal limits-assessment by computed tomography angiography. Interact Cardiovasc Thorac Surg. 2022 Mar 31;34(4):637-644. https://doi.org/10.1093/icvts/ivab308

Reisenauer JS, Said SM, Schaff HV, et al. Outcome of Surgical Repair of Pulmonary Artery Aneurysms: A Single-Center Experience With 38 Patients. Ann Thorac Surg. 2017;104(5):1605-1610. https://doi.org/10.1016/j.athoracsur.2017.03.077

Duijnhouwer AL, Navarese EP, Van Dijk AP, et al. Aneurysm of the Pulmonary Artery, a Systematic Review and Critical Analysis of Current Literature. Congenit Heart Dis. 2016;11(2):102-109. https://doi.org/10.1111/chd.12316

Алеевская А.М., Выборов О.Н., Грамович В.В., Мартынюк Т.В. Особенности дифференциальной диагностики тромбоза лёгочной артерии у пациентов с лёгочной гипертензией (клиническое наблюдение). Пульмонология. 2019;29(5):620-624. https://doi.org/10.18093/0869-0189-2019-29-5-620-624

Aleevskaia A.M., Vyborov O.N., Gramovich V.V., Martynuk T.V. Diagnosis of pulmonary embolism in patients with pulmonary hypertension (a case report). Pulmonologiya. 2019;29(5):620-624. (In Russ.) https://doi.org/10.18093/0869-0189-2019-29-5-620-624

Mesquita SM, Castro CR, Ikari NM et al. Likelihood of left main coronary artery compression based on pulmonary trunk diameter in patients with pulmonary hypertension. Am J Med. 2004 Mar 15;116(6):369-74. https://doi.org/10.1016/j.amjmed.2003.11.015

Galiè N, Saia F, Palazzini M, et al. Left Main Coronary Artery Compression in Patients With Pulmonary Arterial Hypertension and Angina. J Am Coll Cardiol 2017; 69(23):2808-2817. https://doi.org/10.1016/j.jacc.2017.03.597

Kreibich M, Siepe M, Kroll J et al. Aneurysms of the pulmonary artery. Circulation 2015;131(3):310-316. https://doi.org/10.1161/circulationaha.114.012907

Tunariu N, Gibbs SJR, Win Z, et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 2007; 48:680–684. https://doi.org/10.2967/jnumed.106.039438

Архипова О.А., Мартынюк Т.В., Самойленко Л.Е., Сергиенко В.Б., Чазова И.Е. Перфузионная сцинтиграфия лёгких у больных с лёгочной гипертензией различной этиологии. Евразийский Кардиологический Журнал. 2015;(4):20-25. https://doi.org/10.38109/2225-1685-2015-4-20-25

Arkhipova O.A., Martynyuk T.V., Samoilenko L.E., Sergienko V.B., Chazova I.Ye. Perfusion lung scintigraphy in patients with a pulmonary hypertension of a various etiology. Eurasian heart journal. 2015;(4):20-25. (In Russ.) https://doi.org/10.38109/2225-1685-2015-4-20-25

Хроническая тромбоэмболическая лёгочная гипертензия: Руководство для врачей/ Под ред. Т.В. Мартынюк, акад. РАН И.Е. Чазовой. – Москва: ООО «Медицинское информационное агентство», 2023. 416 с. ISBN 978-5-907098-61-9

Chronic thromboembolic pulmonary hypertension: A guide for doctors / Ed. T.V. Martynyuk, acad. RAS I.E. Chazovoy. – Moscow: Medical Information Agency LLC, 2023. 416 p. (In Russ.) ISBN 978-5-907098-61-9

Bajc M, Schümichen C, Grüning T, et al. EANM guideline for ventilation/perfusion single-photon emission computed tomography (SPECT) for diagnosis of pulmonary embolism and beyond. Eur J Nucl Med Mol Imaging. 2019; 46:2429–2451. https://doi.org/10.1007/s00259-019-04450-0

Masy M, Giordano J, Petyt G, et al. Dual-energy CT (DECT) lung perfusion in pulmonary hypertension: concordance rate with V/Q scintigraphy in diagnosing chronic thromboembolic pulmonary hypertension (CTEPH). Eur Radiol 2018; 28:5100–5110. https://doi.org/10.1007/s00330-018-5467-2

Dissaux, B, Le Floch PY, Robin P, et al. Pulmonary perfusion by iodine subtraction maps CT angiography in acute pulmonary embolism: comparison with pulmonary perfusion SPECT (PASEP trial). Eur Radiol 2020;30:4857–4864. https://doi.org/10.1007/s00330-020-06836-3

Johns CS, Swift AJ, Rajaram S, et al. Lung perfusion: MRI vs. SPECT for screening in suspected chronic thromboembolic pulmonary hypertension. J Magn Reson Imaging 2017; 46: 1693–1697. https://doi.org/10.1002/jmri.25714

Swift AJ, Dwivedi K, Johns C, et al. Diagnostic accuracy of CT pulmonary angiography in suspected pulmonary hypertension. Eur Radiol 2020;30:4918–4929. https://doi.org/10.1007/s00330-020-06846-1

Dong C, Zhou M, Liu D, et al. Diagnostic accuracy of computed tomography for chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis. PLoS One 2015;10:e0126985. https://doi.org/10.1371/journal.pone.0126985

Ende-Verhaar YM, Meijboom LJ, Kroft LJM, et al. Usefulness of standard computed tomography pulmonary angiography performed for acute pulmonary embolism for identification of chronic thromboembolic pulmonary hypertension: results of the InShape III study. J Heart Lung Transplant 2019;38:731–738. https://doi.org/10.1016/j.healun.2019.03.003

Guerin L, Couturaud F, Parent F, et al. Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Prevalence of CTEPH after pulmonary embolism. Thromb Haemost 2014;112:598–605. https://doi.org/10.1160/th13-07-0538

Tamura M, Yamada Y, Kawakami T, et al. Diagnostic accuracy of lung subtraction iodine mapping CT for the evaluation of pulmonary perfusion in patients with chronic thromboembolic pulmonary hypertension: correlation with perfusion SPECT/CT. Int J Cardiol 2017;243:538–543. https://doi.org/10.1016/j.ijcard.2017.05.006

Веселова Т.Н., Демченкова А.Ю., Ен М.Ю., др. Оценка перфузии лёгких у больных хронической тромбоэмболической легочной гипертензией методами компьютерной томографии и сцинтиграфии. REJR. 2022;12(2):94-103. https://doi.org/10.21569/2222-7415-2022-12-2-94-103

Veselova T.N., Demchenkova A.Yu., En M.Yu., Ansheles A.A., Martynyuk T.V. The assessment of lung perfusion in patients with chronic thromboembolic pulmonary hypertension using CT and scintigraphy. REJR 2022;12(2):94-103. (in Russ.) https://doi.org/10.21569/2222-7415-2022-12-2-94-103

Meyer GMB, Spilimbergo FB, Altmayer S, et al. Correction to: Multiparametric magnetic resonance imaging in the assessment of pulmonary hypertension: initial experience of a one-stop study. Lung 2018;196:497. https://doi.org/10.1007/s00408-018-0130-x

Swift AJ, Rajaram S, Condliffe R, et al. Diagnostic accuracy of cardiovascular magnetic resonance imaging of right ventricular morphology and function in the assessment of suspected pulmonary hypertension results from the ASPIRE registry. J Cardiovasc Magn Reson 2012; 14:40–50. https://doi.org/10.1186/1532-429x-14-40

100

Hatabu H, Ohno Y, Gefter WB, et al. Expanding applications of pulmonary MRI in the clinical evaluation of lung disorders: Fleischner society position paper. Radiology 2020; 297(2): 286-301. https://doi.org/10.1148/radiol.2020201138

101

Kiely DG, Levin D, Hassoun P, et al. EXPRESS: Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI).Pulm Circ. 2019; 9:2045894019841990. https://doi.org/10.1177/2045894019841990

102

Van de Veerdonk MC, Marcus JT, Bogaard HJ, et al. State of the art: advanced imaging of the right ventricle and pulmonary circulation in humans (2013 Grover Conference series). Pulm Circ 2014;4(2):158–168. https://doi.org/10.1086/675978

103

Vonk Noordegraaf A, Galie N. The role of the right ventricle in pulmonary arterial hypertension. Eur Respir Rev 2011; 20(122):243-253. https://doi.org/10.1183/09059180.00006511

104

Swift AJ, Wild JM, Nagle SK, et al. Quantitative magnetic resonance imaging of pulmonary hypertension a practical approach to the current state of the art. J Thorac Imag 2014; 29(2):68-79. https://doi.org/10.1097/rti.0000000000000079

105

Simpson CE, Damico RL, Kolb TM, Mathai SC, Khair RM, Sato T, Bourji K, Tedford RJ, Zimmerman SL, Hassoun PM. Ventricular mass as a prognostic imaging biomarker in incident pulmonary arterial hypertension. Eur Respir J. 2019 Apr 4;53(4):1802067. https://doi.org/10.1183/13993003.02067-2018

106

Johns CS, Kiely DG, Rajaram S, et al. Diagnosis of pulmonary hypertension with cardiac MRI: derivation and validation of regression models. Radiology. 2019;290:61–68. https://doi.org/10.1148/radiol.2018180603

107

Johns CS, Swift AJ, Hughes PJC, Ohno Y, Schiebler M, Wild JM. Pulmonary MR angiography and perfusion imaging-A review of methods and applications. Eur J Radiol. 2017 Jan;86:361-370. https://doi.org/10.1016/j.ejrad.2016.10.003

108

Rajaram S, Swift AJ, Capener D, et al. Diagnostic accuracy of contrast-enhanced MR angiography and unenhanced proton MR imaging compared with CT pulmonary angiography in chronic thromboembolic pulmonary hypertension. Eur Radiol 2012; 22:310–317. https://doi.org/10.1007/s00330-011-2252-x

109

Alabed S, Shahin Y, Garg P, et al. Cardiac-MRI predicts clinical worsening and mortality in pulmonary arterial hypertension: a systematic review and meta-analysis. JACC Cardiovasc Imaging. 2020;29:S1936-878X(20)30731–2. https://doi.org/10.1016/j.jcmg.2020.08.013

110

Saunders LC, Johns CS, Stewart NJ, et al. Diagnostic and prognostic significance of cardiovascular magnetic resonance native myocardial T1 mapping in patients with pulmonary hypertension. J Cardiovasc Magn Reson. 2018;20:78. https://doi.org/10.1186/s12968-018-0501-8

111

Maschke SK, Schoenfeld CO, Kaireit TF, et al. MRI-derived regional biventricular function in patients with chronic thromboembolic pulmonary hypertension before and after pulmonary endarterectomy. Acad Radiol. 2018;25:1540–1547. https://doi.org/10.1016/j.acra.2018.04.002

112

Sieren MM, Berlin C, Oechtering TH, et al. Comparison of 4D flow MRI to 2D flow MRI in the pulmonary arteries in healthy volunteers and patients with pulmonary hypertension. PLoS One 2019; 14(10):e0224121. https://doi.org/10.1371/journal.pone.0224121

113

Saunders LC, Johns CS, Stewart NJ, Oram CJE, Capener DA, Puntmann VO, Elliot CA, Condliffe RC, Kiely DG, Graves MJ, Wild JM, Swift AJ. Diagnostic and prognostic significance of cardiovascular magnetic resonance native myocardial T1 mapping in patients with pulmonary hypertension. J Cardiovasc Magn Reson. 2018 Dec 3;20(1):78. https://doi.org/10.1186/s12968-018-0501-8

114

Naeije R. Hepatopulmonary syndrome and portopulmonary hypertension. SwissMed Wkly 2003; 133:163–169. https://doi.org/10.4414/smw.2003.10016

115

Rosenkranz S, Howard LS, Gomberg-Maitland M, Hoeper MM. Systemic consequences of pulmonary hypertension and right-sided heart failure. Circulation 2020; 141:678–693. https://doi.org/10.1161/circulationaha.116.022362

116

Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013;369:809–818. https://doi.org/10.1056/NEJMoa1213917

117

Chu JW, Kao PN, Faul JL, Doyle RL. High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. Chest 2002; 122:1668-1673. https://doi.org/10.1378/chest.122.5.1668

118

Шмальц А.А. Динамика дистанции шестиминутной ходьбы как показатель эффективности специфических лёгочных вазодилататоров. Рациональная Фармакотерапия в Кардиологии. 2022;18(3):342-349. https://doi.org/10.20996/1819-6446-2022-06-09

Shmalts A.A. Dynamics of 6-Minute Walk Distance as a Predictor of Efficiency Specific Pulmonary Vasodilators. Rational Pharmacotherapy in Cardiology. 2022;18(3):342-349. (In Russ.) https://doi.org/10.20996/1819-6446-2022-06-09

119

Savarese G, Paolillo S, Costanzo P, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol. 2012; 60(13): 1192–1201. https://doi.org/10.1016/j.jacc.2012.01.083

120

Таран И.Н., Валиева З.С., Мартынюк Т.В., др. Вклад спировелоэргометрии в диагностический алгоритм обследования больных с лёгочной артериальной гипертензией. Медицинский алфавит. Больница (кардиология). 2016;3:19-23.

Taran I.N., Valieva Z.S., Martynyuk T.V., Nakonechnikov S.N., Chazova I.E. Relevance of cardiopulmonary test in diagnostic algoritm in patients with pulmonary arterial hypertension. Medical alphabet. Hospital (cardiology). 2016;3:19-23. (in Russ.)

121

Sherman AE, Saggar R. Cardiopulmonary Exercise Testing in Pulmonary Arterial Hypertension. Heart Fail Clin 2023;19(1):35-43. https://doi.org/10.1016/j.hfc.2022.08.015

122

Dumitrescu D, Nagel C, Kovacs G, et al. Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosis. Heart 2017; 103:774–782. https://doi.org/10.1136/heartjnl-2016-309981

123

Torres-Castro R, Gimeno-Santos E, Vilaró J, et al. Effect of pulmonary hypertension on exercise tolerance in patients with COPD: a prognostic systematic review and meta-analysis.Eur Respir Review 2021; 30:200321. https://doi.org/10.1183/16000617.0321-2020

124

Hoeper MM, Lee SH, Voswinckel R, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006; 48: 2546-2552. https://doi.org/10.1016/j.jacc.2006.07.061

125

Kovacs G, Avian A, Olschewski A, Olschewski H. Zero reference level for right heart catheterisation. Eur Respir J 2013;42:1586–1594. https://doi.org/10.1183/09031936.00050713

126

Куропий Т.С., Данилов Н.М., Матчин Ю.Г. Сосудистые доступы к правым отделам сердца и легочным артериям: современное состояние вопроса. Кардиологический вестник 2022;17(3):23‑28. https://doi.org/10.17116/Cardiobulletin20221703123

Kuropii TS, Danilov NM, Matchin YuG. Vascular accesses for right heart interventions: state of the art. Russian Cardiology Bulletin. 2022;17(3):23-28. (In Russ.) https://doi.org/10.17116/Cardiobulletin20221703123

127

Шмальц А.А., Мартынюк Т.В., Наконечников С.Н. Расчет гемодинамики методом Фика при лёгочной гипертензии, ассоциированной с врождёнными пороками сердца. Евразийский кардиологический журнал 2022;(2):96-102. https://doi.org/10.38109/2225-1685-2022-2-96-102

Shmalts A.A., Martynyuk T.V., Nakonechnikov S.N. Calculation of hemodynamics by the Fick method in pulmonary hypertension associated with congenital heart defects. Eurasian heart journal. 2022;(2):96-102. (In Russ.) https://doi.org/10.38109/2225-1685-2022-2-96-102

128

Opotowsky AR, Hess E, Maron BA, et al. Thermodilution vs estimated Fick cardiac output measurement in clinical practice: an analysis of mortality from the Veterans Affairs Clinical Assessment, Reporting, and Tracking (VA CART) Program and Vanderbilt University. JAMA Cardiol. 2017; 2:1090–1099. https://doi.org/10.1001/jamacardio.2017.2945

129

Viray MC, Bonno EL, Gabrielle ND, et al. Role of pulmonary artery wedge pressure saturation during right heart catheterization: a prospective study. Circ Heart Fail. 2020;13:e007981. https://doi.org/10.1161/circheartfailure.120.007981

130

Kubiak GM, Ciarka A, Biniecka M, et al. Right heart catheterization – background, physiological basics, and clinical implications. J Clin Med 2019;8:1331. https://doi.org/10.3390/jcm8091331

131

Kaemmerer H, Apitz C, Brockmeier K, et al. Pulmonary hypertension in adults with congenital heart disease: Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018;272S:79-88. https://doi.org/10.1016/j.ijcard.2018.08.078

132

Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(14):e698-e800. https://doi.org/10.1161/cir.0000000000000603

133

Xu Q, Yang Y, Geng J, et al. Clinical Study of Acute Vasoreactivity Testing in Patients with Chronic Thromboembolic Pulmonary Hypertension. Chin Med J (Engl) 2017;130(4):382-391. https://doi.org/10.4103/0366-6999.199829

134

Yang Y, Yu Y, Yuan P, et al. Sex differences of hemodynamics during acute vasoreactivity testing to predict the outcomes of chronic thromboembolic pulmonary hypertension. Eur Clin Respir J 2020; 14(7):611-621. https://doi.org/10.1111/crj.13173

135

Юрпольская Л.А., Шмальц А.А. Рентгенография, рентгеновская компьютерная и магнитно-резонансная томография при лёгочной гипертензии, ассоциированной с врождёнными пороками сердца. Детские болезни сердца и сосудов 2021; 18(2):83-93. https://dx.doi.org/10.24022/1810-0686-2021-18-2-83-93

Yurpol’skaya L.A., Shmalts A.A. Х-ray methods and magnetic resonance imaging in pulmonary hypertension associated with congenital heart disease. Children’s Heart and Vascular Diseases. 2021; 18(2):83–93 (in Russ.). https://dx.doi.org/10.24022/1810-0686-2021-18-2-83-93

136

Shimokawahara H, Ogawa A, Mizoguchi H, et al. Vessel stretching is a cause of lumen enlargement immediately after balloon pulmonary angioplasty: intravascular ultrasound analysis in patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 2018;11:e006010. https://doi.org/10.1161/circinterventions.117.006010

137

Weatherald J, Montani D, Jevnikar M, et al. Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev. 2019;28:190023. https://doi.org/10.1183/16000617.0023-2019

138

Morrisroe K, Huq M, Stevens W, et al. Risk factors for development of pulmonary arterial hypertension in Australian systemic sclerosis patients: results from a large multicenter cohort study. BMC Pulm Med. 2016;16:134. https://doi.org/10.1186/s12890-016-0296-z

139

Волков А.В., Мартынюк Т.В. Лёгочная артериальная гипертензия при системных заболеваниях соединительной ткани: современное состояние проблемы. Научно-практическая ревматология 2018;56(4):474−485. https://doi.org/10.14412/1995-4484-2018-474-485

Volkov A.V., Martynyuk T.V. Pulmonary arterial hypertension in systemic connective tissue diseases: the current state of the problem. Rheumatology Science and Practice. 2018;56(4):474-485. (In Russ.) https://doi.org/10.14412/1995-4484-2018-474-485

140

Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 2005;52:3792–3800. https://doi.org/10.1002/art.21433

141

Humbert M, Yaici A, de Groote P, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum. 2011;63:3522–3530. https://doi.org/10.1002/art.30541

142

Coghlan JG, Denton CP, Grunig E, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis:the DETECT study. Ann Rheum Dis. 2014;73:1340–134. https://doi.org/10.1136/annrheumdis-2013-203301

143

Morrell NW, Aldred MA, Chung WK, et al. Genetics and genomics of pulmonary arterial hypertension. Eur Respir J 2019;53:1801899. https://doi.org/10.1183/13993003.01899-2018

144

Kiely DG, Lawrie A, Humbert M. Screening strategies for pulmonary arterial hypertension. Eur Heart J Suppl. 2019; 21:K9–K20. https://doi.org/10.1093/eurheartj/suz204

145

Boon G, Ende-Verhaar YM, Bavalia R, et al. Non-invasive early exclusion of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: the InShape II study. Thorax 2021;76:1002–1009. https://doi.org/10.1136/thoraxjnl-2020-216324

146

Kylhammar D, Kjellstrom B, Hjalmarsson C, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J 2018;39:4175–4181. https://doi.org/10.1093/eurheartj/ehx257

147

Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J 2017; 50:1700740. https://doi.org/10.1183/13993003.00740-2017

148

Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J 2017; 50:1700889. https://doi.org/10.1183/13993003.00889-2017

149

Benza RL, Kanwar MK, Raina A, et al. Development and validation of an abridged version of the REVEAL 2.0 risk score calculator, REVEAL Lite 2, for use in patients with pulmonary arterial hypertension. Chest. 2021;159: 337–346. https://doi.org/10.1016/j.chest.2020.08.2069

150

Zelniker TA, Huscher D, Vonk-Noordegraaf A, et al. The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry. Clin Res Cardiol. 2018;107(6):460-70. https://doi.org/10.1007/s00392-018-1207-5

151

Provencher S, Chemla D, Herve P, et al. Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension. Eur Respir J. 2006;27:114–120. https://doi.org/10.1183/09031936.06.00042705

152

Khirfan G, Naal T, Abuhalimeh B, et al. Hypoxemia in patients with idiopathic or heritable pulmonary arterial hypertension. PLoS One. 2018;13: e0191869. https://doi.org/10.1371/journal.pone.0191869

153

Sitbon O, Chin KM, Channick RN, et al. Risk assessment in pulmonary arterial hypertension: insights from the GRIPHON study. J Heart Lung Transpl. 2020;39:300–309. https://doi.org/10.1016/j.healun.2019.12.013

154

Nickel N, Golpon H, Greer M, et. al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2012; 39:589–596. https://doi.org/10.1183/09031936.00092311

155

Farber HW, Miller DP, McGoon MD, et al. Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. J Heart Lung Transplant. 2015; 34(3):362–368. https://doi.org/10.1016/j.healun.2014.08.020

156

Groepenhoff H, Vonk-Noordegraaf A, van de Veerdonk MC, et al. Prognostic relevance of changes in exercise test variables in pulmonary arterial hypertension. PLoS One. 2013; 8(9):e72013. https://doi.org/10.1371/journal.pone.0072013

157

Schiebler ML, Bhalla S, Runo J, et al. Magnetic resonance and computed tomography imaging of the structural and functional changes of pulmonary arterial hypertension. J Thorac Imaging. 2013; 28(3):178–193. https://doi.org/10.1097/rti.0b013e31828d5c48

158

de Siqueira MEM, Pozo E, Fernandes VR, et al. Characterization and clinical significance of right ventricular mechanics in pulmonary hypertension evaluated with cardiovascular magnetic resonance feature tracking. J Cardiovasc Magn Reson. 2016;18(1):39. https://doi.org/10.1186/s12968-016-0258-x

159

Leuchte HH, El Nounou M, Tuerpe JC, et al. N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. Chest 2007; 131(2):402–409. https://doi.org/10.1378/chest.06-1758

160

Mereles D, Ehlken N, Kreuscher S, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 2006; 114:1482-1489. https://doi.org/10.1161/circulationaha.106.618397

161

Grunig E, MacKenzie A, Peacock AJ, et al. Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial. Eur Heart J 2021;42:2284–2295. https://doi.org/10.1093/eurheartj/ehaa696

162

Morris N.R., Kermeen F.D., Holland A.E. Exercise-based rehabilitation programs for pulmonary hypertension. Cochrane Database of Systematic Reviews. 2017;1(1):CD011285. https://doi.org/10.1002/14651858.cd011285.pub2

163

Chia KSW., Wong PKK., Faux SG. et al. The benefit of exercise training in pulmonary hypertension: a clinical review. Intern Med J 2017; 47(4):361–369. https://doi.org/10.1111/imj.13159

164

Halvorsen S, Mehilli J, Cassese S, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022;43(39):3826-3924. https://doi.org/10.1093/eurheartj/ehac270

165

Диагностика и лечение сердечно-сосудистых заболеваний при беременности 2018. Национальные рекомендации. Российский кардиологический журнал 2018, 3(155):91–134. https://doi.org/10.15829/1560-4071-2018-3-91-134

Diagnosis and treatment of cardiovascular diseases during pregnancy 2018. National guidelines. Russian Journal of Cardiology. 2018;(3):91-134. (In Russ.) https://doi.org/10.15829/1560-4071-2018-3-91-134

166

Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018; 39: 3165–3241. https://doi.org/10.1093/eurheartj/ehy340

167

Hemnes AR, Kiely DG, Cockrill BA, et al. Statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute. Pulm Circ. 2015; 5:435-465. https://doi.org/10.1086/682230

168

Duarte AG, Thomas S, Safdar Z, et al. Management of pulmonary arterial hypertension during pregnancy: a retrospective, multicenter experience. Chest 2013;143:1330–1336. https://doi.org/10.1378/chest.12-0528

169

Hill W., Holy R., Traiger G. EXPRESS: Intimacy, Contraception, and Pregnancy Prevention in Patients with Pulmonary Arterial Hypertension: Are We Counseling Our Patients? Pulm Circ. 2018;10(4):2045894018785259. https://doi.org/10.1177/2045894018785259

170

Gemzell-Danielsson K, Rabe T, Cheng L. Emergency contraception. Gynecol Endocrinol 2013; 29:1–14. https://doi.org/10.3109/09513590.2013.774591

171

Meyer S, McLaughlin VV, Seyfarth HJ, et al. Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey. Eur Respir J. 2013;41:1302–1307. https://doi.org/10.1183/09031936.00089212

172

Thangamathesvaran L, Armenia SJ, Merchant AM. The effect of pulmonary hypertension on inpatient outcomes of laparoscopic procedures. Updates Surg. 2018 Dec;70(4):521-528. https://doi.org/10.1007/s13304-018-0556-y

173

Чазова И.Е, Мартынюк Т.В, Валиева З.С, др. Оценка бремени хронической тромбоэмболической лёгочной гипертензии в Российской Федерации. Терапевтический архив. 2018; 9: 101-109. https://doi.org/10.26442/terarkh2018909101-109

Chazova IE, Martynyuk TV, Valieva ZS, Nakonechnikov SN, Nedogoda SV, Salasyuk AS, Taran IN, Gratsianskaya SE. The economic burden of chronic thromboembolic pulmonary hypertension in Russian Federation. Terapevticheskii arkhiv 2018;90(9):101-109. (In Russ.) https://doi.org/10.26442/terarkh2018909101-109

174

Wang P, Hu L, Yin Y, et al. Can anticoagulants improve the survival rate for patients with idiopathic pulmonary arterial hypertension? A systematic review and meta-analysis. Thromb Res. 2020;196:251–256. https://doi.org/10.1016/j.thromres.2020.08.024

175

Olsson KM, Delcroix M, Ghofrani HA, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation 2014; 129:57–65. https://doi.org/10.1161/circulationaha.113.004526

176

Грацианская С.Е., Мартынюк Т.В., Наконечников С.Н., Чазова И.Е. Проблемные аспекты применения оральных антикоагулянтов у пациентов с легочной артериальной гипертензией различного генеза. Евразийский Кардиологический Журнал. 2017;(4):122-132. https://doi.org/10.38109/2225-1685-2017-4-122-132

Gratsianskaya S.Ye., Martynyuk T.V., Nakonechnikov S.N., Chazova I.Ye. Oral anticoagulants in patients with different forms of pulmonary arterial hypertension, aspects of the problem. Eurasian heart journal. 2017;(4):122-132. (in Russ.) https://doi.org/10.38109/2225-1685-2017-4-122-132

177

Чазова И.Е., Мартынюк Т.В., Филиппов Е.В., соавт. Клинические рекомендации по диагностике и лечению хронической тромбоэмболической лёгочной гипертензии. (2 ЧАСТЬ). Терапевтический архив 2016; 88(10):63-73. https://doi.org/10.17116/terarkh201688663-73

Chazova IE, Martynyuk TV. Clinical guidelines for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension (Part 2). Terapevticheskii arkhiv 2016;88(10):63-73. (In Russ.) https://doi.org/10.17116/terarkh201688663-73

178

Mancuso L, Scordato F, Pieri M, et al. Management of portopulmonary hypertension: new perspectives. World J Gastroenterol. 2013;19:8252–8257. https://doi.org/10.3748/wjg.v19.i45.8252

179

Condliffe R, Kiely DG. Critical care management of pulmonary hypertension. BJA Education 2017; 17(7):228–234. https://doi.org/10.1093/bjaed/mkw074

180

Stickel S, Gin-Sing W, Wagenaar M, Gibbs JSR. The practical management of fluid retention in adults with right heart failure due to pulmonary arterial hypertension. Eur Heart J Suppl. 2019;21:K46–K53. https://doi.org/10.1093/eurheartj/suz207

181

Rich S, Seidlitz M, Dodin E, et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 1998;114:787-792. https://doi.org/10.1378/chest.114.3.787

182

183

Olsson KM, Nickel NP, Tongers J, Hoeper MM. Atrial flutter and fibrillation in patients with pulmonary hypertension. Int J Cardiol 2013; 167:2300–2305. https://doi.org/10.1016/j.ijcard.2012.06.024

184

Hoeper MM, Benza RL, Corris P, et al. Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. Eur Respir J 2019; 53:1801906. https://doi.org/10.1183/13993003.01906-2018

185

Jentzer JC, Mathier, MA. Pulmonary Hypertension in the Intensive Care Unit J Intensive Care Med 2016; 31(6):369–385. https://doi.org/10.1177/0885066615583652

186

Sztrymf B, Souza R, Bertoletti I, et al. Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J 2010; 35:1286–1293. https://doi.org/10.1183/09031936.00070209

187

Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327:76-81. https://doi.org/10.1056/nejm199207093270203

188

Clozel M, Maresta A, Humbert M. Endothelin receptor antagonists. Handb Exp Pharmacol. 2013;218:199–227. https://doi.org/10.1007/978-3-642-38664-0_9

189

Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008; 117:3010–3019. https://doi.org/10.1161/circulationaha.107.742510

190

Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896–903. https://doi.org/10.1056/nejmoa012212

191

Humbert M, Segal ES, Kiely DG, et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J. 2007;30:338–344. https://doi.org/10.1183/09031936.00138706

192

Sitbon J, Bosch J, Cottreel E, et al. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med 2019; 7(7):594-604. https://doi.org/10.1016/s2213-2600(19)30091-8

193

Galie N, Ghofrani HA, Torbicki A, et al, the Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353:2148–2157. https://doi.org/10.1056/nejmoa050010

194

Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003;108:2066-2069. https://doi.org/10.1161/01.cir.0000099502.17776.c2

195

Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119:2894–2903. https://doi.org/10.1161/circulationaha.108.839274

196

Lichtblau, M., Harzheim, D., Ehlken, N., et al. Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension. Lung 193; 1:105–112. https://doi.org/10.1007/s00408-014-9657-7

197

Garraffo R, Lavrut T, Ferrando S, et al. Effect of tipranavir/ritonavir combination on the pharmacokinetics of tadalafil in healthy volunteers. J Clin Pharmacol. 2011;51:1071–1078. https://doi.org/10.1177/0091270010379808

198

Schermuly RT, Janssen W, Weissmann N, et al. Riociguat for the treatment of pulmonary hypertension. Expert Opin Investig Drugs. 2011;20:567–576. https://doi.org/10.1517/13543784.2011.565048

199

Ghofrani H-A, Galiè N, Grimminger F, et al. Riociguat for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2013;369:330-40. https://doi.org/10.1056/nejmoa1209655

200

Ghofrani HA, D’Armini AM, Grimminger F, et al. CHEST-1 Study Group. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013; 369(4):319-329. https://doi.org/10.1056/nejmoa1209657

201

Ghofrani H-A, Grimminger F, Grünig E, et al. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomized, long-term extension trial. Lancet Respir Med. 2016; 4:361–371. https://doi.org/10.1016/s2213-2600(16)30019-4

202

Simonneau G, D’Armini AM, Ghofrani HA et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J 2015;45(5):1293-302. https://doi.org/10.1183/09031936.00087114

203

Olschewski H. Inhaled iloprost for the treatment of pulmonary hypertension. Eur Respir Rev. 2009; 18(111):29–34. https://doi.org/10.1183/09059180.00011111

204

McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174:1257–1263. https://doi.org/10.1164/rccm.200603-358oc

205

Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006;28:691–694. https://doi.org/10.1183/09031936.06.00057906

206

Мартынюк Т.В. Оценка приверженности пациентов с лёгочной гипертензией лечению ингаляционным илопростом (Вентавис): итоги проспективного многоцентрового неинтервенционного исследования IVENT. Системные гипертензии. 2019;16(2):12-27. https://doi.org/10.26442/2075082X.2019.2.190352

Martynyuk TV. Evaluation of compliance of pulmonary hypertension patients to the treatment with inhaled iloprost (Ventavis): results of prospective, multicenter, non-interventional IVENT study. Systemic Hypertension 2019;16(2):12-27. (in Russ.) https://doi.org/10.26442/2075082X.2019.2.190352

207

Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373:2522–2533. https://doi.org/10.1056/nejmoa1503184

208

Резухина Е.А., Родненков О.В., Мартынюк Т.В. Портрет типичного пациента с лёгочной артериальной гипертензией для назначения агониста простациклиновых рецепторов селексипага. Евразийский Кардиологический Журнал 2023;(1):94-99. https://doi.org/10.38109/2225-1685-2023-1-94-99

Rezukhina E.A., Rodnenkov O.V., Martynyuk T.V. Patient and disease characteristics of pulmonary arterial hypertension patients for prostacyclin receptor agonist selexipag treatment initiation. Eurasian heart journal. 2023;(1):94-99. (In Russ.) https://doi.org/10.38109/2225-1685-2023-1-94-99

209

Boucly A, Savale, L, Jaïs, X, et al. Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. Am J of Respir and Crit Care Med. 2021; 204(7):842–854. https://doi.org/10.1164/rccm.202009-3698oc

210

Hoeper MM, Apitz C, Grünig E, et al. Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol 2018; 272S:37–45. https://doi.org/10.1016/j.ijcard.2018.08.082

211

Hoeper MM, McLaughlin VV, Barbera JA, et al. Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomized, controlled AMBITION study. Lancet Respir Med 2016;4:894–901. https://doi.org/10.1016/S2213-2600(16)30307-1

212

McLaughlin VV, Vachiery, JL, Oudiz, RJ, et al. (AMBITION Study Group). Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial. J of Heart and Lung transplantation: the official publication of the International Society for Heart Transplantation. 2019; 38(12):1286–1295. https://doi.org/10.1016/j.healun.2019.09.010

213

Lang I M, Palazzini, M. The burden of comorbidities in pulmonary arterial hypertension. Eur Heart J Suppl. 2019; 21(Suppl K):K21–K28. https://doi.org/10.1093/eurheartj/suz205

214

Шмальц А.А., Горбачевский С.В. Возможности и ограничения для начальной комбинированной специфической терапии лёгочной артериальной гипертензии в Российской Федерации. Терапевтический архив 2020; 92(12):80-85. https://doi.org/10.26442/00403660.2020.12.000840

Shmalts AA, Gorbachevsky SV. Advantages and limitations of initial combination therapy in pulmonary arterial hypertension patients in Russia. Terapevticheskii arkhiv 2020;92(12):80-85. (in Russ.) https://doi.org/10.26442/00403660.2020.12.000840

215

Ляпина И.Н., Зверева Т.Н., Мартынюк Т.В. Возможности комбинированной терапии в лечении пациентов с впервые установленным диагнозом лёгочной артериальной гипертензии промежуточного риска. Consilium Medicum 2022; 24(10):688-695. https://doi.org/10.26442/20751753.2022.10.201875

Lyapina IN, Zvereva TN, Martynyuk TV. Combination therapy of newly diagnosed intermediate-risk pulmonary arterial hypertension: A review. Consilium Medicum. 2022;24(10):688–695. (in Russ.) https://doi.org/10.26442/20751753.2022.10.201875

216

Galiè N, Barbera JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015;373:834–844. https://doi.org/10.1056/nejmoa1413687

217

Hassoun PM, Zamanian RT, Damico R, et al. Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2015;192:1102–1110. https://doi.org/10.1164/rccm.201507-1398oc

218

Sitbon O, Cottin V, Canuet M, et al. Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension. Eur Respir J;56(3):2000673. https://doi.org/10.1183/13993003.00673-2020

219

Macitentan/Tadalafil Fixed-Dose Combination in Pulmonary Arterial Hypertension - A DUE. Presented by Dr. Kelly Chin at the American College of Cardiology Annual Scientific Session (ACC.23/WCC), New Orleans, LA, March 6, 2023. https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2023/03/01/23/47/a-due

220

Chin KM, Sitbon O, Doelberg M, et al. Three versus two-drug therapy for patients with newly diagnosed pulmonary arterial hypertension. J Am Coll Cardiol 2021;78:1393–1403. https://doi.org/10.1016/j.jacc.2021.07.057

221

Thakrar MV, Weatherald JC, Varughese RA, et al. Initial Combination Therapy With Riociguat and Ambrisentan in Pulmonary Arterial Hypertension: A Prospective Open-label Study. J Heart Lung Transplant. 2018;37(4S):S53-S54. https://doi.org/10.1016/j.healun.2018.01.115

222

Satoshi A, Yoshihiro D, Kaori I, et al. Effects of Dual Initial Combination Therapy With Macitentan Plus Riociguat or Macitentan Plus Selexipag on Hemodynamics in Patients With Pulmonary Arterial Hypertension (SETOUCHI-PH Study) – Protocol of a Multicenter Randomized Control Trial. Circ Rep. 2021;3(2):105-109. https://doi.org/10.1253/circrep.cr-20-0133

223

Gaine S, Sitbon O, Channick RN, et al. Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study. Chest 2021; 160(1):277–286. https://doi.org/10.1016/j.chest.2021.01.066

224

McLaughlin V, Channick RN, Ghofrani HA, et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J 2015;46(2):405-413. https://doi.org/10.1183/13993003.02044-2014

225

Galiè, N. Gaine S, Channick R, et al. Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension. Advances in therapy 2022; 39(1):796-810. https://doi.org/10.1007/s12325-021-01898-1

226

Hoeper MM, Simonneau G, Corris PA, et al. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur Respir J 2017;50(3):1602425. https://doi.org/10.1183/13993003.02425-2016

227

Taran IN, Belevskaya AA, Saidova MA, et al. Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular-Pulmonary Arterial Coupling. Lung 2018; 196(6):745-753. https://doi.org/10.1007/s00408-018-0160-4

228

Мартынюк Т.В., Шмальц А.А., Горбачевский С.В., Чазова И.Е. Оптимизация специфической терапии лёгочной гипертензии: возможности риоцигуата. Терапевтический архив 2021; 93(9):1117–1124. https://doi.org/10.26442/00403660.2021.09.201014

Martynyuk TV, Shmalts AA, Gorbachevsky SV, Chazova IE. Optimization of specific therapy for pulmonary hypertension: the possibilities of riociguat. Terapevticheskii arkhiv 2021;93(9):1117-1124. (In Russ.) https://doi.org/10.26442/00403660.2021.09.201014

229

Мартынюк Т.В., Наконечников С.Н., Чазова И.Е. Новые горизонты применения антагониста рецепторов эндотелина второго поколения мацитентана у пациентов с лёгочной гипертензией. Терапевтический архив 2018; 2018:72-80. https://ter-arkhiv.ru/0040-3660/article/view/32480

Martynyuk TV, Nakonechnikov SN, Chazova IY. New horizons for the use of the second generation of endothelin receptor antagonist macitentan in patients with pulmonary hypertension. Terapevticheskii arkhiv 2018;90(4):72-80. (in Russ.) https://ter-arkhiv.ru/0040-3660/article/view/32480

230

Hoeper, MM, Al-Hiti, H, Benza, RL, et al. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. The Lancet Respir Med 2021; 9(6)573–584. https://doi.org/10.1016/s2213-2600(20)30532-4

231

Чазова И.Е., Мартынюк Т.В. от имени авторов. Резолюция экспертного совета по проблеме лёгочной артериальной гипертензии «Меняя парадигму лечения пациентов с ЛАГ». Терапевтический архив 2019;91(3):114-116. https://doi.org/10.26442/00403660.2019.03.000185

Chazova IE, Martynyuk TV. Expert Council resolution on pulmonary arterial hypertension (PAH) "Changing the paradigm of treating patients with pulmonary arterial hypertension". Terapevticheskii arkhiv 2019;91(3):114-116. (in Russ.). https://doi.org/10.26442/00403660.2019.03.000185

232

Li J, Yang ZY, Wang S, et al. Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis. Front Cardiovasc Med 2022;9:977110. https://doi.org/10.3389/fcvm.2022.977110

233

Sandoval J, Gomez-Arroyo J, Gaspar J, Pulido-Zamudio T. Interventional and surgical therapeutic strategies for pulmonary arterial hypertension: Beyond palliative treatments. J Cardiol. 2015; 66(4):304-314. https://doi.org/10.1016/j.jjcc.2015.02.001

234

Gorbachevsky SV, Shmalts AA, Dadabaev GM, et al. Outcomes of Atrioseptostomy with Stenting in Patients with Pulmonary Arterial Hypertension from a Large Single-Institution Cohort. Diagnostics (Basel). 2020;10(9):725. https://doi.org/10.3390/diagnostics10090725

235

Горбачевский С.В., Пурсанов М.Г., Шмальц А.А., др. Результаты атриосептостомии со стентированием у больных с идиопатической и схожими формами лёгочной артериальной гипертензии. Грудная и сердечно-сосудистая хирургия. 2019; 61(2):100-113. https://dx.doi.org/10.24022/0236-2791-2019-61-2-100-113

Gorbachevsky S.V., Pursanov M.G., Shmalts A.A., Dadabaev G.M., Nishonov N.A., Pardaev D.B., Khaсhaturova I.Yu., Alekyan B.G. Results of stent fenestration of the interatrial septum in patients with idiopathic and similar forms of pulmonary arterial hypertension. Russian Journal of Thoracic and Cardiovascular Surgery. 2019;61(2):100–13 (in Russ.). https://dx.doi.org/10.24022/0236-2791-2019-61-2-100-113

236

Шмальц А.А., Нишонов Н.А. Атриосептостомия у больных с лёгочной гипертензией. Грудная и сердечно-сосудистая хирургия. 2015;57(5):18-25.

Shmal’ts A.A., Nishonov N.A. Atrial septostomy for patients with pulmonary hypertension; Grudnaya i Serdechno-Sosudistaya Khirurgiya. 2015;57(5):18-25. (in Russ.)

237

Khan MS, Memon MM, Amin E, et al. Use of balloon atrial septostomy in patients with advanced pulmonary arterial hypertension: a systematic review and meta-analysis. Chest. 2019; 156:53–63. https://doi.org/10.1016/j.chest.2019.03.003

238

Bartolome SD., Torres F. Severe pulmonary arterial hypertension: stratification of medical therapies, mechanical support, and lung transplantation. Heart Fail Rev. 2016; 21(3):347–356. https://doi.org/10.1007/s10741-016-9562-7

239

240

Шмальц А.А., Горбачевский С.В., Мартынюк Т.В., Наконечников С.Н. Тест на вазореактивность при лёгочной гипертензии, ассоциированной с врождёнными пороками сердца. Евразийский кардиологический журнал 2022; 3:58-64. https://doi.org/10.38109/2225-1685-2022-3-58-64

Shmalts A.A., Gorbachevsky S.V., Martynyuk T.V., Nakonechnikov S.N. Vasoreactivity testing in pulmonary hypertension associated with congenital heart disease. Eurasian heart journal. 2022;(3):58-64. (In Russ.) https://doi.org/10.38109/2225-1685-2022-3-58-64

241

Горбачевский С.В., Шмальц А.А., Плотникова Л.Р. Лёгочная гипертензия у детей с врождёнными пороками сердца. М.: ООО «Кедр»; 2018. ISBN 978-5-91487-115-1

Gorbachevsky S.V., Shmalts A.A., Plotnikova L.R. Pulmonary hypertension in children with congenital heart defects. M.: Kedr LLC; 2018. (In Russ.). ISBN 978-5-91487-115-1

242

Барышникова И.Ю., Шмальц А.А. Диагностика лёгочной гипертензии, ассоциированной с врождёнными пороками сердца. Часть 2. Эхокардиография. Российский вестник перинатологии и педиатрии 2021;66:(6):23–32. https://doi.org/10.21508/1027-4065-2021-66-6-23-32

Baryshnikova I.Yu., Shmalts A.A. Diagnosis of pulmonary hypertension associated with congenital heart disease. Part 2. Echocardiography. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2021;66(6):23-32. (In Russ.). https://doi.org/10.21508/1027-4065-2021-66-6-23-32

243

Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J 2021;42(6):563-645. https://doi.org/10.1093/eurheartj/ehaa554

244

Соболев А.В., Шмальц А.А. Эндоваскулярная диагностика лёгочной гипертензии, ассоциированной с врождёнными пороками сердца. Часть 1. Катетеризация сердца и ангиокардиография. Эндоваскулярная хирургия 2021; 8(3):263–71. https://doi.org/https://doi.org/10.24183/2409-4080-2021-8-3-263-271

Sobolev A.V., Shmalts A.A. Endovascular diagnostics of pulmonary hypertension associated with congenital heart defects. Part 1. Cardiac catheterization and angiography. Russian journal of endovascular surgery. 2021;8(3):263-71. (In Russ.) https://doi.org/10.24183/2409-4080-2021-8-3-263-271

245

Горбачевский С.В., Шмальц А.А. Первичное обследование. В кн.: Горбачевский С.В., Шмальц А.А. (ред.) Диагностика лёгочной гипертензии при врождённых пороках сердца. М.: ФГБУ «НМИЦ ССХ им. А.Н.Бакулева» МЗ РФ; 2023:20-34. ISBN: 978-5-7982-0450-2

Gorbachevsky S.V., Shmalts A.A. Primary examination. In the book: Gorbachevsky S.V., Shmalts A.A. (ed.) Diagnosis of pulmonary hypertension in congenital heart defects. M.: A.N. Bakulev National medical research center for cardiovascular surgery Ministry of Health of the Russian Federation; 2023:20-34. (In Russ.) ISBN: 978-5-7982-0450-2

246

Барышникова И.Ю., Шмальц А.А. Эхокардиография. В кн.: Горбачевский С.В., Шмальц А.А. (ред.) Диагностика лёгочной гипертензии при врождённых пороках сердца. М.: ФГБУ «НМИЦ ССХ им. А.Н.Бакулева» МЗ РФ; 2023:35-52. ISBN: 978-5-7982-0450-2

Baryshnikova I.Yu., Shmalts A.A. Echocardiography. In the book: Gorbachevsky S.V., Shmalts A.A. (ed.) Diagnosis of pulmonary hypertension in congenital heart defects. M.: A.N. Bakulev National medical research center for cardiovascular surgery Ministry of Health of the Russian Federation; 2023:35-52. (In Russ.) ISBN: 978-5-7982-0450-2

247

Юрпольская Л.А., Шмальц А.А. Рентгеновская компьютерная и магнитно-резонансная томография. В кн.: Горбачевский С.В., Шмальц А.А. (ред.) Диагностика лёгочной гипертензии при врождённых пороках сердца. М.: ФГБУ «НМИЦ ССХ им. А.Н.Бакулева» МЗ РФ; 2023:53-67. ISBN: 978-5-7982-0450-2

Yurpolskaya L.A., Shmalts A.A. X-ray computed tomography and magnetic resonance imaging. In the book: Gorbachevsky S.V., Shmalts A.A. (ed.) Diagnosis of pulmonary hypertension in congenital heart defects. M.: A.N. Bakulev National medical research center for cardiovascular surgery Ministry of Health of the Russian Federation; 2023:53-67. (In Russ.) ISBN: 978-5-7982-0450-2

248

Соболев А.В., Шмальц А.А. Катетeризация сердца и ангиокардиография. В кн.: Горбачевский С.В., Шмальц А.А. (ред.) Диагностика лёгочной гипертензии при врождённых пороках сердца. М.: ФГБУ «НМИЦ ССХ им. А.Н.Бакулева» МЗ РФ; 2023:68-83. ISBN: 978-5-7982-0450-2

Sobolev A.V., Shmalts A.A. Cardiac catheterization and angiocardiography. In the book: Gorbachevsky S.V., Shmalts A.A. (ed.) Diagnosis of pulmonary hypertension in congenital heart defects. M.: A.N. Bakulev National medical research center for cardiovascular surgery Ministry of Health of the Russian Federation; 2023:68-83. (In Russ.) ISBN: 978-5-7982-0450-2

249

Глушко Л.А., Шмальц А.А. Оценка состояния кардиреспираторной системы. В кн.: Горбачевский С.В., Шмальц А.А. (ред.) Диагностика лёгочной гипертензии при врождённых пороках сердца. М.: ФГБУ «НМИЦ ССХ им. А.Н.Бакулева» МЗ РФ; 2023:109-124. ISBN: 978-5-7982-0450-2

Glushko L.A., Shmalts A.A. Assessment of the state of the cardiorespiratory system. In the book: Gorbachevsky S.V., Shmalts A.A. (ed.) Diagnosis of pulmonary hypertension in congenital heart defects. M.: A.N. Bakulev National medical research center for cardiovascular surgery Ministry of Health of the Russian Federation; 2023:109-124. (In Russ.) ISBN: 978-5-7982-0450-2

250

Шмальц А.А., Горбачевский С.В. Тест на вазореактивность. В кн.: Горбачевский С.В., Шмальц А.А. (ред.) Диагностика лёгочной гипертензии при врождённых пороках сердца. М.: ФГБУ «НМИЦ ССХ им. А.Н.Бакулева» МЗ РФ; 2023:99-108. ISBN: 978-5-7982-0450-2

Shmalts A.A., Gorbachevsky S.V. Vasoreactivity test. In the book: Gorbachevsky S.V., Shmalts A.A. (ed.) Diagnosis of pulmonary hypertension in congenital heart defects. M.: A.N. Bakulev National medical research center for cardiovascular surgery Ministry of Health of the Russian Federation; 2023:99-108. (In Russ.) ISBN: 978-5-7982-0450-2

251

Arvind B, Relan J, Kothari SS. “Treat and repair” strategy for shunt lesions: a critical review. Pulm Circ 2020;10:2045894020917885. https://doi.org/10.1177/2045894020917885

252

Шмальц А.А., Белкина М.В., Горбачевский С.В. Специфические легочные вазодилататоры после операции Фонтена. Детские болезни сердца и сосудов 2017;14(1):16-24. https://dx.doi.org/10.24022/1810-0686-2017-14-1-16-24

Shmal’ts A.A., Belkina M.V., Gorbachevskiy S.V. Specific pulmonary vasodilators after Fontan operation. Detskie bolezni serdtsa i sosudov (Children's Heart and Vascular Diseases). 2017;14(1):16–24 (in Russ.) https://dx.doi.org/10.24022/1810-0686-2017-14-1-16-24

253

Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114:48–54. https://doi.org/10.1161/circulationaha.106.630715

254

Шмальц А.А., Горбачевский С.В. Доказательная база специфических лёгочных вазодилататоров у взрослых с врождёнными пороками сердца. Терапевтический архив. 2021;93(9):1106-1116. https://doi.org/10.26442/00403660.2021.09.201022

Shmalts AA, Gorbachevsky SV. Evidence base for specific pulmonary vasodilators in adults with congenital heart disease. Terapevticheskii arkhiv 2021;93(9):1106-1116. (In Russ.) https://doi.org/10.26442/00403660.2021.09.201022

255

Rubio-Rivas M, Royo C, Simeón CP, et al.. Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44(2):208-19. https://doi.org/10.1016/j.semarthrit.2014.05.010

256

McGoon MD, Miller DP. REVEAL: a contemporary US pulmonary arterial hypertension registry. Eur Respir Rev. 2012;21(123):8-18. https://doi.org/10.1183/09059180.00008211

257

Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023-30. https://doi.org/10.1164/rccm.200510-1668oc

258

Гусева, Н.Г. Системная склеродермия – мультидисциплинарная проблема. Научно-практическая ревматология 2011;49(2):10-14. https://doi.org/10.14412/1995-4484-2011-596

Guseva N.G., Guseva H.G. Systemic scleroderma is a multidisciplinary problem. Rheumatology Science and Practice. 2011;49(2):10-14. (In Russ.) https://doi.org/10.14412/1995-4484-2011-596

259

Волков А.В., Мартынюк Т.В., Юдкина Н.Н. и др. Выживаемость пациентов с лёгочной артериальной гипертонией, ассоциированной с системной склеродермией. Терапевтический архив 2012;84(5):24-28. https://ter-arkhiv.ru/0040-3660/article/view/31020

Volkov AV, Martynyuk TV, Yudkina NN, Danilov NM, Glukhova SI, Guseva NG, Chazova IE, Nasonova VA. Survival of patients with pulmonary arterial hypertension, associated with systemic sclerosis. Terapevticheskii arkhiv 2012;84(5):24-28. (In Russ.) https://ter-arkhiv.ru/0040-3660/article/view/31020

260

Attanasio U, Cuomo A, Pirozzi F, et al. Pulmonary Hypertension Phenotypes in Systemic Sclerosis: The Right Diagnosis for the Right Treatment. Int J Mol Sci. 2020;21(12):4430. https://doi.org/10.3390/ijms21124430

261

Николаева Е.В., Корсакова Ю.О., Курмуков И.А. и др. Возможности эхокардиографического определения давления в лёгочной артерии у пациентов с системными заболеваниями соединительной ткани: данные ревматологического экспертного центра. Научно-практическая ревматология 2015;53(1):51-57. https://doi.org/10.14412/1995-4484-2015-51-57

Nikolaeva E.V., Korsakova Yu.O., Kurmukov I.A., Glukhova S.I., Yudkina N.N., Volkov A.V. Possibilities for echocardiographic determination of pulmonary artery pressure in patients with systemic connective tissue diseases: data of a rheumatology expert center. Rheumatology Science and Practice. 2015;53(1):51-57. (In Russ.) https://doi.org/10.14412/1995-4484-2015-51-57

262

Юдкина Н.Н., Николаева Е.В., Мартынюк Т.В. и др. Клинический субтип системной склеродермии, ассоциированный с лёгочной артериальной гипертензией. Кардиологический вестник. 2017;12(4):66-75.

Yudkina N.N., Nikolaeva E.V., Martynyuk T.V., Volkov A.V. The clinical subtype of systemic scleroderma associated with pulmonary arterial hypertension. Kardiologicheskiy vestnik (Cardiological Bulletin). 2017;4:66–75. (in Russ.)

263

Simpson CE, Damico RL, Hummers L, et al. Serum uric acid as a marker of disease risk, severity, and survival in systemic sclerosis-related pulmonary arterial hypertension. Pulm Circ. 2019;9(3):2045894019859477. https://doi.org/10.1177/2045894019859477

264

Santos-Gomes J, Gandra I, Adão R, et al. An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers. Front Cardiovasc Med 2022;9:924873. https://doi.org/10.3389/fcvm.2022.924873

265

Hao Y, Thakkar V, Stevens W, et al. A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. Arthritis Res Ther. 2015;17(1):7. https://doi.org/10.1186/s13075-015-0517-5

266

Savale L, Guimas M, Ebstein N, Fertin M, et al. Portopulmonary hypertension in the current era of pulmonary hypertension management. J Hepatol 2020;73:130–139. https://doi.org/10.1016/j.jhep.2020.02.021

267

Ryom L, Cotter A, De Miguel R, et al. 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0. HIV Med. 2020;21:617–624. https://doi.org/10.1111/hiv.12878

268

Garry JD, Kolaitis NA, Kronmal R, et al. Pulmonary Hypertension Association Registry Investigators. Anticoagulation in pulmonary arterial hypertension - association with mortality, healthcare utilization, and quality of life: The Pulmonary Hypertension Association Registry (PHAR). J Heart Lung Transplant. 2022;41(12):1808-1818. https://doi.org/10.1016/j.healun.2022.08.019

269

Opravil M, Sereni D. Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era. AIDS (London, England) 2008;22:S35–S40. https://doi.org/10.1097/01.aids.0000327514.60879.47

270

Mularek-Kubzdela T, Ciurzyński M, Kowal Bielecka O, et al. An expert opinion of the Polish Cardiac Society Working Group on Pulmonary Circulation and the Polish Society for Rheumatology on the diagnosis and treatment of pulmonary hypertension in patients with connective tissue disease. Kardiol Pol. 2021;79(7-8):917-929. https://doi.org/10.33963/kp.a2021.0055

271

Конева О.А., Овсянникова О.Б., М. Н. Старовойтова и др. Изолированное снижение диффузионной способности лёгких при системной склеродермии без лёгочной артериальной гипертензии: длительное проспективное наблюдение. Пульмонология. 2016;26(6):708-714. https://doi.org/10.18093/0869-0189-2016-26-6-708-714

Koneva O.A., Ovsyannikova O.B., Starovoytova M.N., Desinova O.V., Smirnov A.V., Alekperov R.T., Anan'eva L.P. Isolated decrease of the lung diffusing capacity in patients with systemic sclerosis without pulmonary arterial hypertension: a long-term prospective study. Pulmonologiya. 2016;26(6):708-714. (In Russ.) https://doi.org/10.18093/0869-0189-2016-26-6-708-714

272

Xanthouli P. Improved Survival for Patients with Systemic Sclerosis-associated Pulmonary Arterial Hypertension: For Real? Am J Respir Crit Care Med. 2023;207(3):238-240. https://doi.org/10.1164/rccm.202210-2006ed

273

Lazaro SM, Quezada Loaiza CA, Rodriguez Padial, et al. Portopulmonary hypertension: prognosis and management in the current treatment era – results from the REHAP registry. Intern Med. 2021;51:355–365. https://doi.org/10.1111/imj.14751

274

Krowka MJ, Miller DP, Barst RJ, et al. Portopulmonary hypertension: a report from the US-based REVEAL Registry. Chest 2012;141:906–915. https://doi.org/10.1378/chest.11-0160

275

Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;170:1212–1217. https://doi.org/10.1164/rccm.200404-445oc

276

Certain MC, Chaumais MC, Jais X, et al. Characteristics and long-term outcomes of pulmonary venoocclusive disease induced by mitomycin C. Ches. 2021;159:1197–1207. https://doi.org/10.1016/j.chest.2020.09.238

277

Montani D, Girerd B, Jais X, et al. Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. Lancet Respir Med 2017;5:125–134. https://doi.org/10.1016/s2213-2600(16)30438-6

278

Меркулов Е.В., Сапельников О.В., Власова Э.Е., др. Осложнения катетерной абляции у пациента с фибрилляцией предсердий: стеноз всех лёгочных вен. Особенности эндоваскулярного лечения. Кардиология 2019;59(5):92-96. https://doi.org/10.18087/cardio.2019.5.10260

Merkulov E.V., Sapelnikov O.V., Vlasova E.E., Nikolaeva O.A., Cherkashin D.I., Pevzner D.V., Gramovich V.V., Omarov O.M., Saidova M.A., Tereshchenko A.S., Arutunyan G.K., Akchurin R.S. Complications of the Catheter Treatment of Atrial Fibrillation: Stenosis of All Pulmonary Veins after Radiofrequency Ablation. Kardiologiia. 2019;59(5):92-96. (In Russ.) https://doi.org/10.18087/cardio.2019.5.10260

279

Assad TR, Hemnes AR, Larkin EK et al. Clinical and Biological Insights Into Combined Post- and Pre-Capillary Pulmonary Hypertension. J Am Coll Cardiol 2016; 68(23):2525-2536. https://doi.org/10.1016/j.jacc.2016.09.942

280

Halpern SD, Taichman DB. Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. Chest 2009;136(1):37-43. https://doi.org/10.1378/chest.08-2784

281

McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42:3599–3726. https://doi.org/10.1093/eurheartj/ehab368

282

Bermejo J, Gonzalez-Mansilla A, Mombiela T, et al. Persistent pulmonary hypertension in corrected valvular heart disease: hemodynamic insights and long-term survival. J Am Heart Assoc. 2021;10: e019949. https://doi.org/10.1161/jaha.120.019949

283

Kovacs G, Herve P, Barbera JA, et al. An official European Respiratory Society statement: pulmonary haemodynamics during exercise. Eur Respir J. 2017;50:1700578. https://doi.org/10.1183/13993003.00578-2017

284

D’Alto M, Romeo E, Argiento P, et al. Clinical relevance of fluid challenge in patients evaluated for pulmonary hypertension. Chest. 2017;151:119–126. https://doi.org/10.1016/j.chest.2016.08.1439

285

Koller B, Steringer-Mascherbauer R, Ebner CH, et al. Pilot study of endothelin receptor blockade in heart failure with diastolic dysfunction and pulmonary hypertension (BADDHY-trial). Heart Lung Circ 2017;26:433–441. https://doi.org/10.1016/j.hlc.2016.09.004

286

Vachiery JL, Delcroix M, Al-Hiti H, et al. Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J 2018;51:1701886. https://doi.org/10.1183/13993003.01886-2017

287

Bermejo J, Yotti R, Garcia-Orta R, et al. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. Eur Heart J. 2018; 39:1255–1264. https://doi.org/10.1093/eurheartj/ehx700

288

Kaluski E, Cotter G, Leitman M, et al. Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonaryhypertension–a multi-center randomized study. Cardiology. 2008;109:273–280. https://doi.org/10.1159/000107791

289

Cao JY, Wales KM, Cordina R, Lau EMT, Celermajer DS. Pulmonary vasodilator therapies are of no benefit in pulmonary hypertension due to left heart disease: A meta-analysis. Int J Cardiol 2018;273:213–220. https://doi.org/10.1016/j.ijcard.2018.09.043

290

Lilly LS. Pathophysiology of Heart Disease: An Introduction to Cardiovascular Medicine (p. 249). Wolters Kluwer Health, 7 th. ed., 2021; Kindle Edition. ISBN-13: 978-1975120597

291

Ляпина И.Н., Теплова Ю.Е., Мартынюк Т.В. Фенотип пациентов с лёгочной гипертензией вследствие патологии левых отделов сердца: особенности патофизиологии и дифференциальной диагностики. Комплексные проблемы сердечно-сосудистых заболеваний 2022;11(4):118-129. https://doi.org/10.17802/2306-1278-2022-11-4-118-129

Lyapina I. N., Teplova Yu. E., Martynyuk T. V. Phenotype of patients with pulmonary hypertension due to left heart disease: features of pathophysiology and differential diagnosis. Complex Issues of Cardiovascular Diseases. 2022;11(4):118-129. (In Russ.) https://doi.org/10.17802/2306-1278-2022-11-4-118-129

292

Obokata M, Reddy YNV, Melenovsky V, et al. Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction. Eur Heart J 2019; 40:689–697. https://doi.org/10.1093/eurheartj/ehy809

293

Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007; 116:1555–1562. https://doi.org/10.1161/circulationaha.107.716373

294

Wu X, Yang T, Zhou Q, Li S, Huang L. Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis. Eur J Heart Fail 2014; 16:444–453. https://doi.org/10.1002/ejhf.47

295

Guazzi M, Samaja M, Arena R, et al. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol. 2007 Nov 27;50(22):2136-44. https://doi.org/10.1016/j.jacc.2007.07.078

296

Obokata M, Reddy YNV, Shah SJ, et al. Effects of interatrial shunt on pulmonary vascular function in heart failure with preserved ejection fraction. J Am Coll Cardiol 2019;74:2539–2550. https://doi.org/10.1016/j.jacc.2019.08.1062

297

Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011 Jul 12;124(2):164-174. https://doi.org/10.1161/circulationaha.110.983866

298

Opitz CF, Hoeper MM, Gibbs JS, et al. Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum. J Am Coll Cardiol 2016; 68:368–378. https://doi.org/10.1016/j.jacc.2016.05.047

299

Hoendermis ES, Liu LC, Hummel YM, et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J 2015;36:2565–2573. https://doi.org/10.1093/eurheartj/ehv336

300

Dachs TM, Duca F, Rettl R, et al. Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial. Eur Heart J 2022; 43(36):3402-3413. https://doi.org/10.1093/eurheartj/ehac389

301

Selim AM, Wadhwani L, Burdorf A, et al. Left ventricular assist devices in pulmonary hypertension group 2 with significantly elevated pulmonary vascular resistance: a bridge to cure. Heart Lung Circ 2019; 28(6):946-952. https://doi.org/10.1016/j.hlc.2018.04.299

302

Bonderman D, Ghio S, Felix SB, et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 2013; 128(5):502-11. https://doi.org/10.1161/circulationaha.113.001458

303

O’Sullivan CJ, Wenaweser P, Ceylan O, et al. Effect of pulmonary hypertension hemodynamic presentation on clinical outcomes in patients with severe symptomatic aortic valve stenosis undergoing transcatheteraortic valve implantation: insights from the new proposed pulmonary hypertension classification. Circ Cardiovasc Interv 2015;8:e002358. https://doi.org/10.1161/circinterventions.114.002358

304

Tigges E, Blankenberg S, von Bardeleben RS, et al. Implication of pulmonary hypertension in patients undergoing MitraClip therapy: results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail 2018; 20:585–594. https://doi.org/10.1002/ejhf.864

305

Gaemperli O, Moccetti M, Surder D, et al. Acute haemodynamic changes after percutaneous mitral valve repair: relation to mid-term outcomes. Heart 2012; 98:126–132. https://doi.org/10.1136/heartjnl-2011-300705

306

Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022;43:561–632. https://doi.org/10.1093/eurheartj/ehab395

307

Schneider SR, Mayer LC, Lichtblau M, et al. Effect of a day-trip to altitude (2500 m) on exercise performance in pulmonary hypertension: randomized crossover trial. ERJ Open Res 2021;7:00314-02021. https://doi.org/10.1183/23120541.00314-2021

308

Groth A, Saxer S, Bader PR, et al. Acute hemodynamic changes by breathing hypoxic and hyperoxic gas mixtures in pulmonary arterial and chronic thromboembolic pulmonary hypertension. Int J Cardiol 2018; 270:262–267. https://doi.org/10.1016/j.ijcard.2018.05.127

309

Zeder K, Avian A, Bachmaier G, et al. Elevated pulmonary vascular resistance predicts mortality in COPD patients. Eur Respir J 2021; 58: 2100944. https://doi.org/10.1183/13993003.00944-2021

310

Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005; 128: 2393-2399. https://doi.org/10.1378/chest.128.4.2393

311

Olsson KM, Hoeper MM, Pausch C, et al. Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry. Eur Respir J 2021; 58: 2101483. https://doi.org/10.1183/13993003.01483-2021

312

Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 189–194. https://doi.org/10.1164/rccm.200401-006oc

313

Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129: 746–752. https://doi.org/10.1378/chest.129.3.746

314

Thabut G, Dauriat G, Stern JB, et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005; 127: 1531–1536. https://doi.org/10.1378/chest.127.5.1531

315

Dawes TJW, McCabe C, Dimopoulos K, et al. Phosphodiesterase 5 inhibitor treatment and survival in interstitial lung disease pulmonary hypertension: A Bayesian retrospective observational cohort study. Respirology. 2023; 28:262-72. https://doi.org/10.1111/resp.14378

316

Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013; 158: 641–649. https://doi.org/10.7326/0003-4819-158-9-201305070-00003

317

Gou Q, Shi R, Zhang X, Meng Q, Li X, Rong X, Gawa Z, Zhuoma N, Chen X. The Prevalence and Risk Factors of High-Altitude Pulmonary Hypertension Among Native Tibetans in Sichuan Province, China. High Alt Med Biol. 2020;21(4):327-335. https://doi.org/10.1089/ham.2020.0022

318

Сарыбаев А.Ш., Сыдыков А.С., Сартмырзаева М.А., др. Высокогорная лёгочная гипертония («болезнь Миррахимова»). Евразийский кардиологический журнал 2016;(4):76-83. https://doi.org/10.38109/2225-1685-2016-4-76-83

Sarybaev A.Sh., Sydykov A.S., Sartmyrzaeva M.A., Maripov A.M., Mamazhakypov A.T., Akunov A.Ch. High altitude pulmonary hypertension («Mirrakhimov's disease»). Eurasian heart journal. 2016;(4):76-83. (In Russ.) https://doi.org/10.38109/2225-1685-2016-4-76-83

319

Sime F, Penaloza D, Ruiz L. Bradycardia, increased cardiac output, and reversal of pulmonary hypertension in altitude natives living at sea level. Br Heart J. 1971;33:647-657. https://doi.org/10.1136/hrt.33.5.647

320

Aldashev AA, Kojonazarov BK, Amatov TA, et al. Phosphodiesterase type 5 and high altitude pulmonary hypertension. Thorax 2005;60:683-687. https://doi.org/10.1136/thx.2005.041954

321

Antezana AM, Antezana G, Aparicio O, et al. Pulmonary hypertension in high-altitude chronic hypoxia: response to nifedipine. Eur Respir J 1998;12:1181-1185. https://doi.org/10.1183/09031936.98.12051181

322

Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS).Eur Heart J 2020;41:543–603. https://doi.org/10.1093/eurheartj/ehz405

323

Swietlik EM, Ruggiero A, Fletcher AJ, et al. Limitations of resting haemodynamics in chronic thromboembolic disease without pulmonary hypertension. Eur Respir J 2019;53:1801787. https://doi.org/10.1183/13993003.01787-2018

324

Wensel R, Francis DP, Meyer FJ, et al. Incremental prognostic value of cardiopulmonary exercise testing and resting haemodynamics in pulmonary arterial hypertension. Int J Cardiol 2013 Aug 20;167(4):1193–1198. https://doi.org/10.1016/j.ijcard.2012.03.135

325

Badagliacca R, Rischard F, Giudice FL, et al. Incremental value of cardiopulmonary exercise testing in intermediate-risk pulmonary arterial hypertension. J Heart Lung Transplant 2022;41:780–790. https://doi.org/10.1016/j.healun.2022.02.021

326

Jenkins DP, Biederman A, D"Armini AM, et al. Operability assessment in CTEPH: Lessons from the CHEST-1 study. J Thorac Cardiovasc Surg. 2016;152(3):669–674. https://doi.org/10.1016/j.jtcvs.2016.02.062

327

Чернявский А.М., Едемский А.Г., Новикова Н.В., др. Хирургическое лечение хронической тромбоэмболической лёгочной гипертензии./ Национальный медицинский исследовательский центр имени Е.Н. Мешалкина; под общей редакцией А.М. Чернявского. — Новосибирск: НМИЦ: Издательство СО РАН, 2019.317 с. ISBN: 978-5-7692-1665-7

Chernyavsky A.M., Edemsky A.G., Novikova N.V., etc. Surgical treatment of chronic thromboembolic pulmonary hypertension./ National Medical Research Center named after E.N. Meshalkina; under the general editorship of A.M. Chernyavsky. — Novosibirsk: National Medical Research Center: Publishing House SB RAS, 2019.317 p. (In Russ.) ISBN: 978-5-7692-1665-7

328

Araszkiewicz A, Darocha S, Pietrasik A, et al. Balloon pulmonary angioplasty for the treatment of residual or recurrent pulmonary hypertension after pulmonary endarterectomy. Int J Cardiol. 2019;278: 232–237. https://doi.org/10.1016/j.ijcard.2018.10.066

329

Madani MM, Auger WR, Pretorius V, et al. Pulmonary endarterectomy: recent changes in a single institution’s experience of more than 2,700 patients. Ann Thorac Surg 2012;94:97–103. https://doi.org/10.1016/j.athoracsur.2012.04.004

330

Lankeit M, Krieg V, Hobohm L, et al. Pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2018;37:250–258. https://doi.org/10.1016/j.healun.2017.06.011

331

Акчурин Р.С., Мершин К.В., Табакьян Е.А., др. Хирургическое лечение хронической тромбоэмболической лёгочной гипертензии: современные тенденции и собственный опыт. Евразийский Кардиологический Журнал. 2016; 2:40-47. https://doi.org/10.38109/2225-1685-2016-2-40-47

Akchurin R.S., Mershin K.V., Tabakyan E.A., Latypov R.S., Gazizov V.V., Tsyrenov D.D. Surgical treatment of chronic thromboembolic pulmonary hypertension: modern trends and own experience. Eurasian heart journal. 2016;(2):40-47. (In Russ.) https://doi.org/10.38109/2225-1685-2016-2-40-47

332

D’Armini AM, Morsolini M, Mattiucci G, Grazioli V, Pin M, Valentini A, et al. Pulmonary endarterectomy for distal chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg 2014;148:1005–1011. https://doi.org/10.1016/j.jtcvs.2014.06.052

333

Newnham M, Bunclark K, Abraham N, et al. CAMPHOR score: patient-reported outcomes are improved by pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. Eur Respir J. 2020;56:1902096. https://doi.org/10.1183/13993003.02096-2019

334

Чернявский А.М., Едемский А.Г., Чернявский М.А., др. Пятилетние результаты хирургического лечения пациентов с хронической постэмболической лёгочной гипертензией Хирургия. Журнал им. Н.И. Пирогова. 2017;2:21-24. https://doi.org/10.17116/hirurgia2017221-24

Cherniavskiĭ AM, Edemskiĭ AG, Cherniavskiĭ MA, Tarkova AR, Kliver EN, Ivanov SN. 5-year surgical results in patients with chronic postembolic pulmonary hypertension. Pirogov Russian Journal of Surgery = Khirurgiya. Zurnal im. N.I. Pirogova. 2017;(2):21-24. (In Russ.) https://doi.org/10.17116/hirurgia2017221-24

335

Taboada D, Pepke-Zaba J, Jenkins DP, et al. Outcome of pulmonary endarterectomy in symptomatic chronic thromboembolic disease. Eur Respir J. 2014;44:1635–1645. https://doi.org/10.1183/09031936.00050114

336

Quadery SR, Swift AJ, Billings CG, et al. The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension. Eur Respir J. 2018;52:1800589. https://doi.org/10.1183/13993003.00589-2018

337

Jaïs X, Brenot P, Bouvaist H, et al. Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study. Lancet Respir Med. 2022;10(10):961-971. https://doi.org/10.1016/s2213-2600(22)00214-4

338

Delcroix M, Staehler G, Gall H, et al. Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients. Eur Respir J. 2018;52:1800248. https://doi.org/10.1183/13993003.00248-2018

339

Benza RL, Farber HW, Frost A, et al. REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat. J Heart Lung Transplant. 2018;37:836–843. https://doi.org/10.1016/j.healun.2018.02.015

340

Humbert M, Farber HW, Ghofrani HA, et al. Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019;53:1802004. https://doi.org/10.1183/13993003.02004-2018

341

Bunclark K, Newnham M, Chiu YD, et al. A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension. J Thromb Haemost. 2020;18:114–122. https://doi.org/10.1111/jth.14649

342

Humbert MS, Simonneau G, Pittrow D, et al. Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant. 2022;41:716–721. https://doi.org/10.1016/j.healun.2022.02.002

343

Валиева З.С., Мартынюк Т.В. Выбор специфической и антикоагулянтной терапии у пациентов с впервые выявленной хронической тромбоэмболической легочной гипертензией в зависимости от статуса операбельности. Российский кардиологический журнал. 2023;28(3):5231. https://doi.org/10.15829/1560-4071-2023-5231

Valieva Z.S., Martynyuk T.V. Choice of specific and anticoagulant therapy in patients with newly diagnosed chronic thromboembolic pulmonary hypertension, depending on operability status. Russian Journal of Cardiology. 2023;28(3):5231. (In Russ.) https://doi.org/10.15829/1560-4071-2023-5231

344

Ordi-Ros J, Saez-Comet L, Perez-Conesa M, et al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial. Ann Intern Med 2019;171:685–694. https://doi.org/10.7326/m19-0291

345

Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018;132:1365–1371. https://doi.org/10.1182/blood-2018-04-848333

346

Ghofrani HA, Simonneau G, D’Armini AM, et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respir Med. 2017;5:785–794. https://doi.org/10.1016/s2213-2600(17)30305-3

347

Reesink HJ, Surie S, Kloek JJ, et al. Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg. 2010;139:85–91

348

Reichenberger F, Voswinckel R, Enke B, et al. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hyper- tension. Eur Respir J. 2007;30:922–927. https://doi.org/10.1183/09031936.00039007

349

Данилов Н.М., Матчин Ю.Г., Мартынюк Т.В. и др. Баллонная ангиопластика лёгочных артерий при неоперабельной хронической тромбоэмболической лёгочной гипертензии. Сonsilium Medicum 2016;5:59-61. https://consilium.orscience.ru/2075-1753/article/view/94466

Danilov NM, Matchin YG, Chazova IE. Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension. Consilium Medicum 2016;18(5):59-61. (In Russ.) https://consilium.orscience.ru/2075-1753/article/view/94466

350

Mahmud E, Behnamfar O, Ang L,et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Interv Cardiol Clin 2018;7:103–117. https://doi.org/10.1016/j.iccl.2017.09.003

351

Ogawa A, Matsubara H. After the dawn-balloon pulmonary angioplasty for patients with chronic thromboembolic pulmonary hypertension. Circ J 2018;82:1222-1230. https://doi.org/10.1253/circj.cj-18-0258

352

Ogawa A, Satoh T, Fukuda T, et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: results of a multicenter registry. Circ Cardiovasc Qual Outcomes. 2017;10:e004029. https://doi.org/10.1161/circoutcomes.117.004029

353

Wiedenroth CB, Ghofrani HA, Adameit MSD, et al. Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension. Pulm Circ 2018; 8:2045894018783996. https://doi.org/10.1177/2045894018783996

354

Fukui S, Ogo T, Morita Y, et al. Right ventricular reverse remodelling after balloon pulmonary angioplasty. Eur Respir J 2014;43:1394–1402. https://doi.org/10.1183/09031936.00012914

355

Fukuda K, Hiroshi Date H, Dоi S, et al. Guidelines for the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017). Circ J 2019;83(4):842-945. https://doi.org/10.1253/circj.cj-66-0158

356

Яровой С.Ю., Данилов Н.М., Матчин Ю.Г., Чазова И.Е. Структурные изменения легочных артерий после транслюминальной баллонной ангиопластики у пациентов с хронической тромбоэмболической легочной гипертензией. Евразийский Кардиологический Журнал. 2020;(4):12-20. https://doi.org/10.38109/2225-1685-2020-4-12-20

Yarovoy S.Y., Danilov N.M., Matchin Yu.G., Chazova I.E. Structural changes of the pulmonary arteries after balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. Eurasian heart journal. 2020;(4):12-20. (In Russ.) https://doi.org/10.38109/2225-1685-2020-4-12-20

357

Andreassen AK, Ragnarsson A, Gude E, et al. Balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. Heart 2013;99:1415–1420. https://doi.org/10.1136/heartjnl-2012-303549

358

Kurzyna M, Darocha S, Pietura R, Pietrasik A, Norwa J, Mańczak R, et al. Changing the strategy of balloon pulmonary angioplasty resulted in a reduced complication rate in patients with chronic thromboembolic pulmonary hypertension. A single-centre European experience. Kardiol Pol 2017;75:645–654. https://doi.org/10.5603/kp.a2017.0091

359

Olsson KM, Wiedenroth CB, Kamp JC, Breithecker A, Fuge J, Krombach GA, et al. Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience. Eur Respir J 2017;49:1602409. https://doi.org/10.1183/13993003.02409-2016

360

Godinas L, Bonne L, Budts W, et al. Balloon pulmonary angioplasty for the treatment of nonoperable chronic thromboembolic pulmonary hypertension: single-center experience with low initial complication rate. J Vasc Interv Radiol 2019;30:1265-1272. https://doi.org/10.1016/j.jvir.2019.03.023

361

Lang IM, Andreassen AK, Andersen A, et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: a clinical consensus statement of the ESC working group on pulmonary circulation and right ventricular function. Eur Heart J 2023;44(29):2659-2671. https://doi.org/10.1093/eurheartj/ehad413

362

Shinkura Y, Nakayama K, Yanaka K, et al. Extensive revascularisation by balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension beyond haemodynamic normalisation. EuroIntervention 2018;13:2060-2068. https://doi.org/10.4244/eij-d-17-00157

363

Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 2015;373:823-833. https://doi.org/10.1056/nejmoa1501035

364

Danilov NM, Matchin YuG, Sagaydak OV, et al. Antecubital vein access for balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension: safe new approach. Russian Open Medical Journal 2019;8:e0107. https://doi.org/10.15275/rusomj.2019.0107

365

Данилов Н.М., Яровой С.Ю., Елфимова Е.М., др. Клинические и рентгенологические аспекты реперфузионного отёка лёгких после транслюминальной баллонной ангиопластики лёгочных артерий у пациентов с хронической тромбоэмболической лёгочной гипертензией. Системные гипертензии. 2022;19(3):23-30. https://doi.org/10.38109/2075-082X-2022-3-23-30

Danilov N.M., Yarovoy S.Yu., Elfimova E.M., Mikhailova O.O., Litvin A.Yu., Danilushkin Yu.V., Matchin Yu.G., Chazova I.E. Clinical and radiological aspects of reperfusion pulmonary edema after balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. Systemic Hypertension. 2022;19(3):23-30. (In Russ.) https://doi.org/10.38109/2075-082X-2022-3-23-30

366

Jensen KW, Kerr KM, Fedullo PF, et al. Pulmonary hypertensive medical therapy in chronic thromboembolic pulmonary hypertension before pulmonary thromboendarterectomy. Circulation 2009;120(13):1248-54. https://doi.org/10.1161/circulationaha.109.865881

367

Валиева З.С., Мартынюк Т.В., Наконечников С.Н., Чазова И.Е. Характеристика пациентов с хронической тромбоэмболической лёгочной гипертензией по данным российского национального регистра. Терапевтический архив. 2021;93(9):1058-1065. https://doi.org/10.26442/00403660.2021.09.201037

Valieva ZS, Martynyuk TV, Nakonechnikov SN, Chazova IE. Characteristics of patients with chronic thromboembolic pulmonary hypertension according to the Russian National Registry. Terapevticheskii arkhiv. 2021;93(9):1058-1065. (in Russ.) https://doi.org/10.26442/00403660.2021.09.201037

368

Ni JR, Yan PJ, Liu SD, et al. Diagnostic accuracy of transthoracic echocardiography for pulmonary hypertension: a systematic review and meta-analysis. BMJ Open. 2019; 9(12):e033084. https://doi.org/10.1136/bmjopen-2019-033084

369

Gall H, Yogeswaran A, Fuge J, et al. Validity of echocardiographic tricuspid regurgitation gradient to screen for new definition of pulmonary hypertension. EClinicalMedicine. 2021;34:100822. https://doi.org/10.1016/j.eclinm.2021.100822

370

D'Alto M., Di Maio M., Romeo E, et al. Echocardiographic probability of pulmonary hypertension: a validation study. Eur Respir J 2022;60:2102548. https://doi.org/10.1183/13993003.02548-2021

371

Sydykov A, Mamazhakypov A, Maripov A, et al. Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders. Int J Environ Res Public Health. 2021;18(4):1692. https://doi.org/10.3390/ijerph18041692

372

Soria R, Egger M, Scherrer U, et al. Pulmonary artery pressure and arterial oxygen saturation in people living at high or low altitude: systematic review and meta-analysis. J Appl Physiol 2016;121(5):1151-1159. https://doi.org/10.1152/japplphysiol.00394.2016

373

Maripov A, Mamazhakypov A, Karagulova G, et al. High altitude pulmonary hypertension with severe right ventricular dysfunction. Int J Cardiol. 2013;168(3):e89-e90. https://doi.org/10.1016/j.ijcard.2013.07.129

374

Grover RF, Vogel JH, Voigt GC, et al. Reversal of high altitude pulmonary hypertension. Am J Cardiol 1966;18:928-932. https://doi.org/10.1016/0002-9149(66)90443-7

375

Maripov A, Muratali Uulu K, Satybaldyev S, Kushubakova N, Sarybaev A. Reversal of pulmonary hypertension in a patient with chronic mountain sickness after relocation to low altitude. J Clin Diagn Res. 2021 y;15(5):OD09-OD10. http://dx.doi.org/10.7860/JCDR/2021/48309.14886

376

Singh I, Khanna PK, Lal M, et al. High-altitude pulmonary hypertension. Lancet. 1965;2(7404):146-50. https://doi.org/10.1016/s0140-6736(65)90229-1

377

Richalet JP, Rivera-Ch M, Maignan M, et al. Acetazolamide for Monge's disease: efficiency and tolerance of 6-month treatment. Am J Respir Crit Care Med. 2008;177(12):1370-6. https://doi.org/10.1164/rccm.200802-196oc

378

Ishikura K, Yamada N, Ito M, et al. Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ. J. Off. J. Jpn. Circ. Soc. 2006;70:174-178. https://doi.org/10.1253/circj.70.174

379

Kojonazarov B, Myrzaakhmatova A, Sooronbaev T, et al. Effects of fasudil in patients with high-altitude pulmonary hypertension. Eur Respir J. 2012;39:496-498. https://doi.org/10.1183/09031936.00095211

380

Sommer N, Ghofrani H-A, Pak O, et al. Current and future treatments of pulmonary arterial hypertension. Br J Pharmacol. 2021;178:6-30. https://doi.org/10.1111/bph.15016

381

Grimminger F, Schermuly RT, Ghofrani H-A. Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat Rev Drug Discov. 2010;9:956-970. https://doi.org/10.1038/nrd3297

The authors declare that there are no conflicts of interest present.